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ABSTRACT 
IMPACT OF DIETARY BIOACTIVE COMPONENTS IN CHRONIC 
DISEASES USING NUTRIGENOMICS, NUTRIEPIGENOMICS, AND 
METAGENOMICS APPROACHES 
BIJAYA PRASAD UPADHYAYA 
2016 
Chronic diseases that include seven of the top ten leading causes of premature 
deaths in the United States demand more than eighty percent of all health care cost. 
Although typical Western diets--high fat (HF), low fiber and low vegetables-- are 
frequently associated with increased risk for chronic diseases like obesity, metabolic 
syndrome (MetS), type 2 diabetes, cardiovascular diseases (CVD), and cancer, there is a 
lack of mechanistic understanding of a causal relationship between diet and disease 
phenotypes, particularly in a clinical setting. This dissertation research aimed to address 
this research gap through the effects of wheat fiber-derived resistant starch type 4 (RS4) 
in MetS, maternal HF diet on offspring cardiovascular health, and cruciferous vegetables-
derived phenethyl isothiocyanate (PEITC) in cancer prevention, using next generation 
“omics” technologies and molecular nutrition approaches. 
RS4 flour (30%) enriched differential abundance of 71 bacterial operational 
taxonomic units in fecal samples obtained from Hutterite participants having MetS. RS4 
not only showed butyrogenic effects in humans but also increased cecal mass and 
butyrate concentration in mice, signifying the role of dietary fiber in bowel health. 
 xiv 
	
Butyrate induced tri-methylated lysine 27 on histone 3 (H3K27me3) in the promoter of 
nuclear factor-kappa-B1 (NFκB1) contributing to epigenetic repression of intestinal 
inflammation in mice. A genome-wide differential chromatin landscape of histone 
modifications (H3Ac, H3K4me3, and H3K27me3) was observed in offspring due to their 
maternal HF (40% kcal) diet, implicating the increased risks for obesity, diabetes, and 
CVDs beyond one generation. PEITC inhibited cancer stem cell (CSC) marker aldehyde 
dehydrogenase 1 (ALDH1) with concomitant induction of oxidative stress and apoptosis 
in cervical CSCs, conferring improved therapeutic outcomes in cancer patients. 
This dissertation presents a body of translational research work on diet-gene 
interaction, which is expected to contribute to the fast-growing nutrigenomics 
knowledgebase and inform about  (1) diet-responsive gut microbiota and metabolites, (2) 
fetal-reprogramming to prevent adult-onset of chronic diseases, and (3) chemo-preventive 
strategies to improve therapeutic outcomes of cancer by minimizing recurrence and 
metastasis. Together, these findings will contribute to future dietary recommendations 
that are expected to be more precise than at current times. 
 
Keywords: Butyrate, Cancer stem cells, Clinical research, Gestational diabetes, Gut 
microbiota, High fat diet, Histone modifications, Metabolic syndrome, Phenethyl 
isothiocyanate, Preclinical disease model, Resistant starch type 4 
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CHAPTER 1 . INTRODUCTION AND DISSERTATION ORGANIZATION 
1.1. Nutrigenomics and Nutriepigenomics in Health 
Since the time of Hippocrates (460-370 BC) food is considered a medicine in 
maintaining health and wellness. The Human Genome Project (1990-2003) followed by 
various post-genomic research initiatives along with the advent of modern 
biotechnological tools has opened numerous opportunities to establish the validity of 
this notion experimentally, and to explain how environmental factors like diet alter the 
expression and/or structure of an individual’s genetic makeup. This new era of 
molecular nutrition is unfolding in terms of individual response to nutrients due to own 
genetic variation (i.e., nutrigenetics), or in terms of the effects of food bioactives on the 
regulation of gene expression (i.e., nutrigenomics) [1]. Hence, nutrigenomics is a 
discovery science, which aims to understand how diet-gene interactions influences 
metabolic and disease pathways, how this regulation is disturbed in the early phase of 
diet-related diseases, and how dietary interventions prevent the individuals at risk from 
such diseases [2] (Figure 1.1). 
Furthermore, nutriepigenomics deals with the elucidation of how biologically 
active dietary components modulate the landscape of a gene position in chromatin or 
chromosome, without changing the DNA sequence, and regulate the turning “on” and 
“off“ the genes epigenetically [3]. However, many common diseases, such as obesity, 
cancer, diabetes, and cardiovascular diseases are polygenic in nature, which means that 
they arise from the dysfunction in a cascade of genes. Therefore, dietary intervention to 
prevent the onset of such diseases is a complex and challenging goal, and requires a 
thorough understanding of molecular nutrition, genetics, physiology, pathology, 
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biochemistry, bioinformatics, and wide array of  “omics” technologies [4]. Powerful 
new parallel sequencing technologies have allowed for large scale genomic analysis of 
complex microbial populations, once unidentifiable due to inability to culture in vitro. 
These metagenomic approaches allow for both qualitative and quantitative microbial 
population analysis in both health and diseases. 
 
1.2. Gut Microbiota and Metabolic Diseases 
The human gut is colonized by trillions of microorganisms; including hundreds 
of different species of bacteria, viruses and fungi that outnumber the host cells by 10 
fold [5]. These gut microbiota not only directly associates with the food that we eat [6, 
7] but also involve in triggering immune cells underlying a single layer of gut 
epithelium. There exists a mutually beneficial association between the resident gut 
microbiota and a healthy host [8]. Commensal bacteria co-evolved with their hosts and 
hence are not pathogenic under normal or healthy conditions. The dominant residents of 
human gut are Gram-negative strict anaerobes, including Bacteriodes, Bifidobacterium, 
Fusobacterium, Eubacterium, Peptostreptococcus, and Atopobium [9]. However, under 
specific conditions, this ecological homeostasis cannot be maintained, leading to 
pathologic imbalance of gut microbiota, termed dysbiosis. Dysbiosis	triggers a multitude 
of chronic human disease conditions, such as inflammatory bowel diseases (IBD) [10], 
intestinal cancers [11], obesity [12], type 2 diabetes [13], atherosclerosis [14], and 
alteration of bone metabolism [15]. Hence,	the	three-way	interaction	among	the	diet,	gut	microbiota	and	host	play	a	critical	role	in	shaping	intestinal	as	well	as	extra-intestinal	health	and	diseases. 
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The microbiota being an essential component in gut microenvironment plays a 
critical role in the pathogenesis of intestinal as well as extra-intestinal diseases. As	most	of	the	bacteria	reside	in	the	human	gut	in	close	proximity	to	intestinal	epithelium,	their	composition	and	metabolism	are	directly	influenced	by	the	foods	ingested.	Given	the	ability	to	impact	on	the	fine	balance	between	health	and	disease,	it	is	reasonable	to	tailor	novel	strategies	to	prevent	bowel	inflammation	and	associated	comorbidities	through	dietary	interventions	(Figure	1.2).	 
 
1.3. Fiber diet, resistant starch and Metabolic Syndrome 
While dietary fiber is associated with a lower risk of obesity and cancer [16], 
diets high in refined carbohydrates are associated with significant increases in obesity 
and metabolic syndrome (MetS) [17]. Based on International Diabetes Federation (IDF) 
criteria, MetS is identified with central obesity (≥102 cm in men and ≥88 cm in women) 
plus any two of the following four parameters: 
1. Raised blood pressure: systolic BP ≥130 mm Hg or diastolic BP ≥85 mm Hg or 
any medication for hypertension, 
2. Raised triglycerides: ≥150 mg/dl (1.7 mmol/l) or history of medication for 
triglycerides abnormality, 
3. Reduced high-density lipoprotein (HDL) cholesterol: < 40 mg/dl (1.03 mmol/l) 
in males and < 50 mg/dl (1.29 mmol/l) in females or history of medication for 
HDL abnormality, and 
4. Raised fasting blood glucose level: ≥ 100 mg/dl or previously diagnosed with 
type 2 diabetes mellitus [18]. 
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Considering a typical Western lifestyle with high-fat and high-carbohydrates in 
diets with less physical activity, the chances of acquiring MetS is even higher. 
According to American Heart Association and National Health and Nutrition 
Examination Survey 1999–2010, almost 34% of American adults are affected by MetS 
that multiply a person's risk for heart disease, diabetes and stroke [19].  
Prebiotics are non-digestible and selectively fermentable complex 
oligosachharides or other ingredients that confer health benefits due to selective changes 
in composition or activity of the gut microbiota [20]. Digestive fermentation of complex 
carbohydrates and fibers results in the formation of a number of SCFAs, which 
positively modulate colonic health through several mechanisms [21].  
The major source of carbohydrate in the human diet is starch. There are five 
types of RS: physically inaccessible RS1 found in partly milled grains and seeds; 
resistant granules RS2 found in raw potato, green banana, some legumes, and high-
amylose starches; retrograded RS3 found in cooked and cooled potato, bread, and 
cornflakes; and chemically modified RS4 as etherized, esterified, or cross-bonded 
starches [22] along with a newly reported amylose-lipid complex RS5 (Table 1.1). RS4 
resists digestion in the small intestine due to its chemical modification, and passes to the 
colon where it is subjected to gut microbiota-mediated fermentation [23]. It has been 
shown that dietary interventions with RS4 attenuated various risk factors for metabolic 
syndrome (MetS) characterized by several conditions such as insulin-resistance, 
dyslipidemia, abdominal obesity, and hypertension that ultimately lead to atherosclerosis 
and cardiovascular disease (CVD) [24, 25]. Diets high in resistant starch (RS) 
profoundly affect the types of fecal bacteria, including species related to Ruminococcus 
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bromii, which can contribute to starch degradation and SCFA production [26]. An 
increased consumption of RS produces more butyrate, which is associated with higher 
insulin sensitivity and improved glycemic control [27], suggesting the role of gut 
microbiota in promoting the host health [24]. 
RS has certain advantages over other dietary fibers in terms food applications. 
For instance, RS has a white, tasteless powder-like texture with a small particle size, 
rendering it more desirable for a variety of bakery products, pasta products, cereals, and 
snacks, etc. to increase the dietary-fiber contents and improve the quality of the final 
products [28]. This forms the basis for objective of chapter 2 to investigate how RS4 
modulates gut microbiota and its metabolite SCFAs in individuals with signs of MetS. 	
1.4. Short-Chain Fatty Acids, Gut Epithelial Integrity and Mucosal Immunity Gut	epithelial	cells	are	tightly	packed	with	paracellular	tight-junction	proteins	(TJPs)	to	act	as	a	defensive	barrier	between	luminal	microbes	and	underlying	immune	cells.	Only	some	antigen	presenting	cells	(APCs)	are	well	trained	to	constantly	sample	the	luminal	microbes	that	distinguish	luminal	microflora	from	pathogens,	without	alarming	mucosal	immunity	[29].	However,	in	case	of	pathogenicity,	these	APCs	recognize	the	pathogens	based	on	their	pathogen	associated	molecular	pattern	and	signal	to	respective	toll-like	receptor	(TLR)	cascades,	resulting	into	inflammation	and	associated	immune	response	[30].	Therefore,	it	is	most	necessary	to	maintain	the	gut	barrier	function	to	control	the	chronic	low-grade	inflammation.		
A recent study found a strong association between lower fiber intake, and 
subsequent lower production of SCFAs with early tumor development in patients at high 
risk of CRC [31]. Further, butyrate oxidation is the primary energy source for human 
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colonocytes and is strongly anti-inflammatory by inhibiting production of inflammatory 
cytokines and inhibition of inflammatory pathways like NFκB activation [21]. 	
SCFA butyrate is the product of bacterial carbohydrates and fiber 
polysaccharides fermentation in the human gut [32, 33]. Butyrate has both trophic and 
bioactive functions on host cells. Besides correcting the altered ratio of gut bacteria [34], 
butyrate can modulate intestinal and colonic inflammation by protecting against the 
potential pro-inflammatory molecules due to its ability to modulate gene expression 
[35], which could lead to an anti-inflammatory effect and inhibit the progression of low-
grade chronic inflammation. Epigenetically, butyrate has been linked to histone 
deacetylase (HDAC) inhibiting properties in several cell lines and is considered to be a 
promising treatment for cancer. Butyrate might mitigate low-grade chronic inflammation 
by suppressing the transcription of inflammatory genes through H3K27 tri-methylation 
[36] or acting as an HDAC inhibitor [37] in colon cancer cells. This serves the basis of 
our objective of chapter 3 that dietary RS4 improves the luminal effects of butyrate on 
inducing histone modifications (e.g. H3K4Me3) by regulating chemokines (e.g. CCL2) 
and transcription factors (e.g. NFκB). 
 
1.5. High-Fat Diet, Gestational Diabetes and Fetal Programming 
Stimuli such as over nutrition, physical inactivity, and aging can result in chronic 
low-grade inflammation, leading to insulin resistance and diabetes in genetically or 
metabolically predisposed individuals [38]. Obesity epidemics is rising world wide [39], 
and alarmingly 34.4% of US women are obese in their child-bearing stage [40], resulting 
the higher incidence of gestational diabetes mellitus (GDM). GDM is one of the most 
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common complications in pregnancy that occurs when high fasting glucose (> 92−125 
mg/dL) associated glucose intolerance is first diagnosed at any time of pregnancy, or in 
between 24 and 28 weeks in particular [41]. Of note, 17.8% (9.3-25.5%) of overall 
pregnancies in the US are affected by GDM [42].  
Over nutrition or maternal high fat (HF) diet during the pregnancy is another 
critical factor to shape the adult onset of metabolic diseases in the offspring [43, 44]. In 
GDM, a food plan focused on controlling carbohydrate often adds up more fat in the diet 
[45] in order to meet the caloric needs of a rapidly growing fetus. Since heart constantly 
demands a high-energy source to maintain its contractile activity, heart prefers to utilize 
all fuel sources including fatty acids [46]. Hence, the quantity as well as quality of the 
dietary fat during pregnancy plays a major role in cardiometabolic health outcomes in 
offspring above and beyond the pregnant mother [47].  
Altogether, the interaction between fetal and maternal environment and 
modulation of gene expression that starts very early in life and that can pass across 
generations due to epigenetic modifications such as DNA methylation and covalent 
posttranslational histone modifications [48]. This forms the rationale of chapter 4 that 
maternal HF diet affects streptozotocin (STZ)-induced gestational diabetes to alter the 
metabolic programming in the offspring using a neonatal heart tissues in suitable rat 
model. 
 
1.6. Phenethyl Isothiocyanate, Cancer-Stem Cells and Cervical Cancer 
Cancer statistics shows that cervical cancer is the fourth most common cancer in 
women, and the seventh overall, with an estimated 528,000 new cases in 2012 
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worldwide, while it remains the most common cancer in women in Eastern and Middle 
Africa. Interestingly, 87% of cervical cancer deaths occur only in the less developed 
regions [49], possibly due to less screening techniques.  
Cancer stem cells (CSCs), a subset of cancer cells (0.1- 30%) with self-renewal 
and differentiation potential, have been implicated in tumor initiation, maintenance, 
metastasis, and recurrence of a number of cancer types [50, 51]. To identify and isolate 
CSCs from within a heterogeneous population of cancer cells, recent studies have shown 
that aldehyde dehydrogenase family 1 (ALDH1) is a CSC marker that associates with 
tumor malignancy and self-renewal properties of stem cells in different tumors, 
including breast [52], colon [53], and cervical [54, 55] cancers.  
PEITC is a dietary bioactive compound derived from common Brassicacae 
family cruciferous vegetables, such as watercress, broccoli, cabbage, and cauliflower 
[56]. PEITC possesses anti-inflammatory [57, 58] and chemopreventive activity against 
various cancers, including colon [59], breast [60], cervical [61, 62] cancers. PEITC has 
no apparent toxicity, as revealed from safety studies in rats and dogs, even when 
administered in high doses determined by NOEL (no-observed-adverse-effect-level) 
[63]. Remarkably, undergoing clinical trials in the US has elucidated the protective role 
of PEITC against lung cancer (NCT00691132). This is the basis of our working 
hypothesis under chapter 5 that PEITC selectively targets chemo-and-radiotherapy 
resistant cancer initiating CSC) in a suitable mouse model. 
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1.7. Dissertation Organization 
The whole dissertation research has yielded five research papers as described in 
subsequent chapters. Two of them are published, one is accepted for publication, and the 
remaining two papers are in preparation. These chapters are preceded by a general 
“Introduction”, while specific literature review is provided within the specific chapter, 
followed by a general “Conclusion”. All the figures and tables belonging to the same 
chapter are placed at the end of each chapter. The references are cited in a numbered 
fashion as they appear in the text and are compiled altogether at the end of this 
document.  
 10 
	
 
 
 
Figure 1.1. Nutrigenomics 
A model emphasizing nutrient-gene interaction responsible for health and disease status 
(modified from Peter Gillies [2]). 
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Figure 1.2. A dynamic extrinsic and intrinsic factors affecting gut epithelial 
permeability.  
Epithelial monolayer separates luminal gut microbiota and their metabolites from 
underlying mucosal immune cells. Tight-junction proteins (TJPs) hold adjacent 
epithelial cell together to prevent paracellular bacterial translocation into the gut 
mucosa. The disequilibrium or dysbiosis determines the fate of epithelial cells whether 
to activate mucosal immune system through microbial pattern recognition receptor 
called toll-like receptors (TLRs) or to activate enterocyte apoptosis to turnover. Dietary 
bioactive components like PEITC and dietary fiber like RS4 modulate gut epithelial 
integrity maintaining the fine balance between health and disease. 
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Table 1.1. Types of resistant starch and their food sources (modified from Topping 
and Clifton [22]) 
Types of Resistant Starch Examples of Occurrence 
RS1; physically inaccessible 
 
Partly milled grains and seeds 
RS2; resistant granules Raw potato, green banana, some 
legumes, and high-amylose starches 
RS3; retrograded Cooked and cooled potato, bread, and 
cornflakes 
RS4; chemically modified Etherized, esterified, or cross-bonded 
starches (used in processed foods) 
RS5; amylose-lipid complex 
Stearic	acid-complexed	high-amylose	starch 
RS: Resistant starch
 13 
	
CHAPTER 2 . IMPACT OF DIETARY RESISTANT STARCH TYPE 4 ON 
HUMAN GUT MICROBIOTA AND IMMUNOMETABOLIC FUNCTIONS 
 
Related publication: Upadhyaya, B. et al. Impact of dietary resistant starch type 4 on 
human gut microbiota and immunometabolic functions. Sci. Rep. 6, 28797; doi: 
10.1038/srep28797 (2016) 
 
2.1. Abstract 
Dietary modulation of the gut microbiota impacts human health. Here we 
investigated the hitherto unknown effects of resistant starch type 4 (RS4) enriched diet on 
gut microbiota composition and short-chain fatty acid (SCFA) concentrations in parallel 
with host immunometabolic functions in twenty individuals with signs of metabolic 
syndrome (MetS). Cholesterols, fasting glucose, glycosylated hemoglobin, and 
proinflammatory markers in the blood as well as waist circumference and % body fat 
were lower post intervention in the RS4 group compared with the control group. 16S-
rRNA gene sequencing revealed a differential abundance of 71 bacterial operational 
taxonomic units, including the enrichment of three Bacteroides species and one each of 
Parabacteroides, Oscillospira, Blautia, Ruminococcus, Eubacterium, and 
Christensenella species in the RS4 group. Gas chromatography–mass spectrometry 
revealed higher fecal SCFAs, including butyrate, propionate, valerate, isovalerate, and 
hexanoate after RS4-intake. Bivariate analyses showed RS4-specific associations of gut 
microbiota with host metabolic functions and SCFA levels. Here we show that dietary 
RS4 induced changes in the gut microbiota are linked to its biological activity in 
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individuals with signs of MetS. These findings have potential implications for dietary 
guidelines in metabolic health management.  
Keywords: 16S-rRNA gene sequencing, gut microbiota, resistant starch type 4, 
short chain fatty acids, bowel health 
 
2.2. Introduction 
Metabolic syndrome (MetS) encompasses co-morbidities like obesity, 
dyslipidaemia, hypertension, insulin resistance, and hyperglycaemia, which increase the 
risk of cardiovascular diseases [64], the leading cause of death in the US [65]. Although 
it is possible to manage these co-morbidities with dietary/lifestyle changes and/or 
therapeutic interventions, the overall prevalence of MetS is rising worldwide [65, 66]. 
One contributing factor could be non-adherence to healthy dietary practices beyond the 
short term, as convenience and taste remain the strongest determinants of food choices 
[67, 68]. In that context, our recent double-blind study allowed participants to maintain 
their habitual dietary practices during the intervention without adapting to any change 
[25]. This was possible due to the neutral and adaptable organoleptic properties of the 
resistant starch (RS) type 4 (RS4), a wheat-derived food-ingredient, used for the 
intervention.  
Different chemical properties contribute to the functional differences between five 
RS types, particularly in terms of fermentability and its influence on the microbiota in the 
gut  [69]-[24].  Fermentable carbohydrates such as RS4, may potentially increase colonic 
short-chain fatty acid (SCFA) production [70].  However, there remains a dearth of well-
controlled intervention studies that have comprehensively examined the influence of RS4 
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on host physiological, gut microbiome, and SCFA changes [71-73].  One study reported 
influence of RS4 in healthy individuals, unrelated to any metabolic condition [24]. Other 
published studies regarding metabolic health benefits of RS4 involved animal models 
[74-76].  However, due to various metabolic adaptations in MetS patients, they may not 
always benefit from the information generated in healthy humans or animal models [77].  
Taken together, there is a critical need for well-designed studies in individuals with MetS 
that systematically connects the influence of a functional and adaptable food ingredient 
on the gut microbial community, bacterial metabolites like SCFAs, and host metabolic 
functions. 
In our trial, the RS4-group had an improved lipid profiles and body composition 
[25]. Since RS4 is indigestible, we hypothesized that the health benefits of RS4 are 
derived from its ability to influence the gut microbial community structure, which may, 
in turn, be linked to altered bacterial fermentation and SCFA production [22]. Therefore, 
here, in selected participants with MetS, we retrospectively examined the changes in the 
microbiota composition and the SCFA production in the gut, measured the concentrations 
of three circulatory adipocytokine markers, and estimated the macronutrient and caloric 
intake during the intervention period.  Also, the host anthropometric and metabolic 
parameters were reanalysed in this cohort to show microbe-microbe and host-microbe 
interactions. 
 
2.3. Materials and Methods 
Subjects 
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Participants in this study included a subset of the parent cohort consisting of 20 
individuals who originally participated in a dietary intervention with RS4 [25]. Briefly, 
this study was conducted in an adult population, consisting of both males and females, 
from two Hutterite colonies in eastern South Dakota, USA. The Hutterites are a culturally 
homogeneous Caucasian population of Central European ancestry. The parent trial is 
registered in clinicaltrials.gov (NCT01887964). From 40 participants who had signs of 
metabolic syndrome at baseline, 26 subjects submitted stool samples at all four data 
collection time points. Out of 26, 20 subjects (10 from each of the two colonies) were 
included in the current investigation as their fecal samples were adequate to carry out 
both sequencing and short chain fatty acid (SCFA) analyses (Figure 2.1). The selected 
cohort included 12 females and eight males, aged 32-77 (Table 2.1). Exclusion criteria 
included pregnancy, lactation, long-term antibiotic therapy, immune compromised state, 
cancer, and other conditions that would affect the ability to provide informed consent or 
comply with the protocol.   
 
Test Diets 
Participants consumed control flour (CF) and resistant starch type 4(RS4) flours 
as described in Nichenametla et al.  [25]. RS4 flour was made by substituting 30% (v/v) 
of the CF with RS4 (Fibersym RW, MGP Ingredients Inc., Atchison, KS).  The sequence 
of flour consumption was randomly assigned to the colonies. Dietary intake was assessed 
by using a 3-day (2 weekdays and 1 weekend day) semi-quantitative food-frequency 
questionnaire, customized to include foods that Hutterites frequently consume,  mostly 
consisting of items cooked from raw ingredients.  Evidence show that the Hutterites 
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consume more fresh produce in summer and preserved or frozen food in winter resulting 
into a diet-influenced shifts in microbiome [78]. Since the study period did not overlap 
with winter months, the impact of seasonal variation on gut microbiome was not 
considered.  Diet analysis was performed using Nutritionist Pro (Axxya Systems, 
Redmond, WA, USA) to obtain macro-nutrient breakdown of the consumed diets. Diet 
information was collected using a self-administered semi-quantitative food frequency 
questionnaire and was analysed using Nutritionist Pro (Axxya Systems, Redmond, WA, 
USA). Anthropometric, blood lipids, glycaemic parameters, and blood pressure 
measurement data were obtained from the parent study and reanalysed in this sub-cohort 
[25].  
 
Study design 
The original trial [25] was conducted as a two-period, total 26-week long double 
blind (participants–investigators), placebo-controlled, cluster cross-over intervention 
(Figure 2.1a).  Each intervention period (CF and RS4) was for 12 weeks with a washout 
time of two weeks in between. All data and bio specimens were collected on-site from 
both colonies at baseline, 12, 14, and 26 weeks except body composition analyses, which 
were carried out at baseline, 12 and 26 weeks. A modified CONSORT flow chart is 
provided (Figure 2.1b).  The study was conducted under free-living conditions, and no 
dietary restrictions were imposed. Gastrointestinal symptoms and stool consistency were 
scored based on a one-on-one interview with the participants [25]. Current and past 
medical information were obtained at each visit, which included medication or dietary 
supplement use, menopausal status, medical conditions, and hospital stays. Seven-day 
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physical activity-recall questionnaires were administered by trained staff to assess any 
atypical physical activity.  
 
Anthropometric measurements 
Height, weight, waist circumference, and blood pressure were measured at the 
beginning and at the end of each intervention period following standard procedures that 
were previously described [79]. Briefly, height was determined using a stadiometer and 
recorded to the nearest 0.5 cm. Body weight was measured on an electronic scale (Seca 
GmbH & Co., Hamburg, Germany) with the subjects in light clothes and no shoes and 
was recorded to the nearest 0.1 kg. Waist circumference was measured at the navel using 
a tension-sensitive, non-stretching Gulick tape and recorded to the nearest 0.5 cm. 
Blood pressure was measured with a digital sphygmomanometer in a sitting position. 
Body composition (fat mass and fat-free mass) was determined by total-body, dual-
energy, x-ray absorptiometry (DXA) scanning (Hologic QDR Discovery A, Waltham, 
MA) as described previously [80]. Fat mass is presented as % body fat in paper.   
 
Blood biochemistry 
Overnight fasting blood was collected by venepuncture in vacutainer tubes (BD 
Biosciences, Franklin Lakes, NJ). Fasting blood glucose, total cholesterol (TC), Low-
Density-Lipoprotein cholesterol (LDL), High-density-Lipoprotein cholesterol (HDL), 
non-HDL cholesterol (non-HDL), triglycerides were determined using the Cholestech 
LDX point-of-care analyzer (Alere Inc, Waltham, MA), lipid profile and glucose 
cassettes (Lipid Profile GLU, Alere Inc, Waltham, MA), following the manufacturers’ 
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instructions. Postprandial glucose was determined 2 h after either breakfast or the noon 
meal by using a FreeStyle Freedom Lite blood glucose meter (Abbott Diabetes Care Inc, 
Alameda, CA), following the manufacturer’s instructions. Participants typically 
consumed a food item made with test flour during the meal prior to the postprandial 
glucose test. Glycosylated hemoglobin (HbA1C) was determined by an enzyme-based 
colorimetric assay using the Human HbA1C kit (Crystal Chem, Downers Grove, IL), 
following the manufacturer’s instructions. Each sample was run in duplicate, and a batch 
control was used to account for inter-assay variation. HbA1C levels were expressed as 
the percentage of total hemoglobin. Two markers of inflammation, interleukin 6 (IL6) 
and tissue necrotic factor-α were determined (in duplicate) in serum using Human ELISA 
Ready-SET-Go kits, following the manufacturer’s instructions (eBioscience, San Diego, 
CA). Plasma adiponectin levels, an indicator of metabolic functions, were detected by 
Human Adiponectin Radioimmunoassay following the manufacturer’s instructions 
(Linco Research, St. Charles, MO). Inter- and Intra-assay coefficients of variance were 
5.0% and 11.7%, respectively. 
 
Fecal SCFA analysis by gas chromatography-mass spectrometry (GC-MS) 
SCFAs were derivatized to their corresponding butyl esters (SCFABE) followed 
by GC-MS analyses using a GC-MS 5977A and HP-5MS UI capillary column from the 
same manufacturer (Agilent, Wilmington, DE, USA). The data were expressed in mg/gm 
of fecal sample. To prepare fecal samples for SCFA analyses, 800-1000 mg fecal sample 
was homogenized and added to a glass tube containing 1 ml of internal standard (2-
ethylbutyric acid in 1-butanol, 1 mg/mL). Organic solvent hexane and derivatizing agents, 
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hydrogen chloride 1-butanol or Boron trifluoride 1-butanol (both from Sigma-Aldrich, St. 
Louis, MO), were then added with vortexing between each addition. Boron trifluoride 1-
butanol and hydrogen chloride 1-butanol were used to create butyl-esters for SCFA 
detection. Samples were then sonicated and placed in water bath (90-100 0C) for 1h. 
Once cooled to room temperature, water and additional hexane were added to the samples 
and centrifuged at 3000g for two min. The organic layer (~2 mL) was transferred into a 
sampling vial with 150 µL inserts, finally adding a pinch (~10 mg) of anhydrous sodium 
sulphate to remove the residual water. Fecal extracts were stored at -20 0C until further 
analysis. 
GC-MS analyses were performed with an GC-MS 5977A (Agilent Technologies, 
Wilmington, DE, USA) and an HP-5MS UI capillary column (30 m x 0.25mm, 0.2 µm 
thickness, Agilent, Wilmington, DE, USA). Hydrogen was used as carrier gas at 1.9 
mL/min constant flow and a typical injection volume was 1 µL in the split mode (1:10). 
The separation of SCFA butyl esters was achieved using an oven temperature program as 
follow: initial elution temperature was 55 0C for 4 min then 5 0C/min to 120 0C and then 
20 0C/min to 220 0C for 10 min. The selective mass detector was operated in the ‘single 
ion monitoring and scan’ (SIM/Scan) mode. The source was maintained at 150 0C and the 
electron energy was 70 eV.  
 
Community structure analysis of gut microbes 
Stool DNA was extracted using the QIAamp DNA Stool Mini Kit (QIAGEN, 
Valencia, CA) according to the manufacturer’s instructions. All samples were quantified 
via the Qubit® Quant-iT dsDNA Broad-Range Kit (Invitrogen, Life Technologies, Grand 
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Island, NY). Sample DNAs were sent to Second Genome (South San Francisco, CA) for 
metagenome sequencing, and operational taxonomic unit (OTU) identification. Briefly, 
samples were enriched for bacterial 16S V4 rDNA region, DNA was amplified utilizing 
fusion primer designed against the Illumina (San Diego, CA) flow cell adapters and 
indexing barcodes. Each sample was PCR-amplified with two differently bar coded V4 
fusion primers. For each sample, amplified products were concentrated using a solid-
phase reversible immobilization method for the purification of PCR products and 
quantified by electrophoresis using an Agilent 2100 Bioanalyzer® (Agilent Technologies, 
Santa Clara, CA). Sequencing was carried out using Illumina MiSeq platform following 
standard protocols for 250 cycles with custom primers designed for paired-end 
sequencing. Using Quantitative Insights Into Microbial Ecology or QIIME  [81] and 
generated custom scripts (Second Genome), sequences were quality-checked and 
demultiplexed to determine exact matches to the supplied DNA barcodes. Resulting 
sequences were then searched against the Greengenes reference database of 16S rRNA 
gene sequences, clustered at 97% by uclust (closed reference OTU picking). The longest 
sequence from each OTU was then assigned taxonomic classification via Mothur's 
Bayesian classifier, trained against the Greengenes database clustered at 98%. For 
unidentified Greengenes OTUs, we cross referenced with closest hits from NCBI 16S 
rRNA database with query cover (>90%), identity (>87%), and E value (<0.01). Raw 
sequences are deposited in NCBI sequence read archive (SRA, accession number 
SRP035338), belonging to BioProject accession number PRJNA308315. 
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Statistical analyses 
Data analyses were performed using two approaches. Effects of CF and RS4 
interventions were determined by comparing end-point data, while effects of RS4 
intervention alone was presented by comparing the data before and after RS4 intervention. 
Linear mixed effects models (SAS MIXED procedure) were used to compare the effects 
of RS4 and CF on biological parameters. All models included variables for colony and 
season, where colony was a surrogate for randomization sequence and season was a 
surrogate for crossover treatment period. Because the crossover design used only two 
clusters (colonies), and any carryover effect might be confounded by cluster sampling 
effect (colony effects), thus a carryover effect could not be independently evaluated in the 
mixed models. Covariates for age, sex, baseline value of the outcome variable, change in 
total calorie intake were evaluated for their association with the response variables, and 
covariates that significantly affected at least one outcome variable were retained in the 
final model as fixed effects. The final models included season, colony, sex, age, and 
initial baseline value of the response variable as fixed effects.  
When appropriate data were presented for either all-participants or stratifying 
participants based on missing data or outliers in microbial changes as our observations 
concur with a prior report of large inter-subject variations in response to RS4 [24].  For 
microbiome analyses one subject was excluded (n=19) because of Lactobacillus probiotic 
supplement use during the RS4 intervention period. For multivariate analysis PhyCA-
Stats™ software package (Second Genome Inc, South San Francisco, CA) was utilized. 
Differences in the bacterial taxa and host phenotypes among time points were determined 
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by paired t-test or student’s t-test as appropriate. If the data were not normally distributed, 
values were subjected to logarithmic transformations as indicated. 
Two approaches for sampling normalization were employed to account for 
uneven sequencing depth during data analyses on metagenome sequencing. First, taxa 
were filtered to those present in at least one of the samples, selecting 55,079 sequences 
from each sample before calculating community-wide dissimilarity measures. This 
facilitated calculations of microbial relative abundances (Figures 2.2, 2.4b, 2.6b, 2.7, and 
2.8), and principal coordinate analyses (Figure 2.3). Second, the samples were 
normalized to 1 million counts. Thus the shift in microbial profile between the samples or 
groups was calculated based on per million sequences, which facilitated calculations of 
71 differentially abundant OTUs or species (Figures 2.4a and 2.4c).  
We used various R-packages (http://www.r-project.org/) for downstream data 
analyses on gut microbiome.  Package edgeR 
(http://www.bioconductor.org/packages/release/bioc/html/edgeR.html) [82] which has 
the distinct benefit of increasing the sensitivity of detecting differentially abundant 
features, was utilized to control for inter-subject variability because of  a model-based 
normalization to adjust for varying sequencing depths.  This approach of identifying 
differentially abundant taxa between treatments borrows from the RNA sequencing 
literature testing for differential gene expression. These methods have recently been 
demonstrated to effectively translate to microbiome analyses [83], offering a robust 
method with options for paired sample comparisons even for experiments with minimal 
levels of biological replication.  To correct for multiple comparisons, a false discovery 
rate correction was used to correct for p-values (adjusted p is represented as q). In order 
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to generate correlation matrices and heat maps, several R-packages, namely Hmisc 
(http://CRAN.R-project.org/package=Hmisc) [84], corrplot (http://CRAN.R-
project.org/package=corrplot) [85], gplots (http://CRAN.R-project.org/package=gplots) 
[86], and ecodist (https://CRAN.R-project.org/package=ecodist) [87] were used. 
Significant variation in microbiome baseline values between intervention-groups were 
ruled out using a Permutational Multivariate Analysis of Variance that also confirmed the 
effectiveness of the washout period. Two-dimensional Principal Coordinate Analysis 
(PCoA) followed by Adonis test was used for plotting dissimilarity values so that the 
similar data points get closer to each other.  Statistical analyses were carried out using 
Sigma Plot software (Systat Software, Inc., San Jose, CA) and the data were presented as 
means±S.E.M, unless otherwise noted. A p value of 0.05 or less was considered 
significant, while a p value of 0.05 to 0.09 was considered trend or approaching 
significance.  
 
2.4. Results 
Baseline physiologic, metabolic, and microbiome characteristics of the study 
participants  
All twenty participants who had signs of metabolic syndrome at baseline and 
submitted adequate stool samples at four data collection time points were included in the 
current investigation (Figure 2.1), which allowed for comparison of the gut microbial and 
SCFA profiles before and after the interventions and also between the endpoints of the 
RS4 and CF (control) interventions. Potential adverse gastrointestinal side effects from 
the interventions were not evaluated in this cohort since none were observed in the parent 
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cohort [25]. Baseline characteristics of 20 participants are summarized in Table 2.1. 
Taxonomic classification of a total of 55,079 sequences (present in at least one of the 
samples) were sorted into 5,949 OTUs, of which ~78% were associated with the phylum 
Firmicutes and ~9% with the phylum Bacteroidetes (Figure 2.2).  
 
Washout was effective in restoring microbiome characteristics  
Before switching the RS4 and CF diets in the cross-over study design, all the 
participants were supplied with CF during the 2-week washout period in order to avoid 
the potential carry-over effects of the RS4 intervention. For endpoint comparison 
between the RS4 and CF groups, it was necessary to check for a consistent baseline prior 
to each treatment period. Using permutational multivariate analysis of variance for 
distance matrices, no significant differences were observed among the starting 
microbiomes of the RS4 and CF groups (data not shown), which also confirmed that the 
two-week washout was effective and that any differences observed post-intervention are 
due to the intervention itself. 
 
Macronutrient intake pattern did not vary during the study  
Variation in macronutrient intake and total calories consumed can potentially 
influence the gut microbiota [88], thereby confounding the effects of the intervention. 
Although a large number of food options are offered at each meal, Hutterites have 
relatively small interpersonal differences in diet due to common meal planning, kitchen, 
and dining practices. No significant differences in overall macronutrients and caloric 
intake were observed between the baseline and post-intervention time periods, with the 
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exception of dietary fiber (Table 2.2). Dietary fiber intake, analysed separately from total 
carbohydrate intake, was significantly higher in the RS4 group (p<0.001), due to RS4 
being classified as a prebiotic dietary fiber (Table 2.2). The average calories (~1,774 
Kilocalories) consumed at baseline were estimated to come from carbohydrate (~49%), 
protein (~17%), and fat (~34%). These values fall within the Dietary Reference Intakes 
(DRI) for macronutrients, which are 45–65%, 10–35%, and 20–35% for carbohydrate, 
protein, and fat, respectively [89].  Of particular interest, saturated fat (12.6%, DRI<10%) 
and cholesterol (415 mg, DRI<300 mg) intakes were higher, while daily fiber intake was 
lower (18 g at baseline, DRI 20–30 g) than recommended in the participants studied.   
 
Differential post-intervention effects of the RS4 diet compared with the CF diet on 
the gut microbiota 
The current understanding is that, in studies without a proper control group, inter-
individual variation in gut microbial composition in adults frequently offsets the smaller 
changes induced by dietary interventions [71]. To address this problem, we compared 
microbial composition and abundance post RS4 compared with post CF intervention. 
Three taxa, all unclassified species of Firmicutes, differentially shifted between CF and 
RS4 treatments in eight male participants. Similarly, a differential effect of RS4 was 
observed in 16 Firmicutes taxa, with the most numerous genus being Enterococcus, 
which was significantly enriched after CF intake in 12 female participants (data not 
shown). No distinct trend for Firmicutes to Bacteroidetes ratio was observed in male or 
female participants (data not shown). The dominance of Firmicutes and Bacteroidetes 
was consistent with previous results, as reported in Hutterite [78] and other populations 
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[90]. The Shannon diversity index was not associated with the age of the participants 
(r=−0.2, p>0.05, data not shown). Likewise, the total diversity of the microbiota assessed 
from the Shannon diversity index did not significantly change after either CF or RS4 
interventions (data not shown).  
Principal coordinate analysis showed 26% and 13% variations on axes 1 and 2, 
respectively, indicating a major shift between the two groups (p=0.01, Figure 2.3). The 
RS4 diet differentially modified 71 microbial OTUs (q<0.05), including enrichment of 
four each of Ruminococcus and Blautia, two each of Bacteroides and Oscillospira, and 
one Parabacteroides OTUs (data not shown). Of the 71 OTUs, 65 belonged to the 
phylum Firmicutes. The three Bacteroidetes OTUs all increased in abundance with RS4 
relative to the CF treatment, while OTUs belonging to Firmicutes had a mixed response 
(data not shown). At the species level, some species were significantly enriched in the 
RS4 group, including three Bacteroides species (>121.2 fold, q<0.05) along with Blautia 
glucerasea (2497.1 fold, q<0.001), Christensenella minuta (2.4x106 fold, q<0.001), 
Eubacterium oxidoreducens (7723.2 fold, q<0.01), Oscillospira spp. (2528.4 fold, 
q<0.01), Ruminococcus lactaris (1.2x105 fold, q<0.001), and Parabacteroides distasonis 
(8642.2 fold, q<0.001), while some were significantly decreased in abundance in this 
group, including  pathogenic Enterococcus casseliflavus (–13603.2 fold, q<0.001)  and 
Streptococcus cristatus (–229.7 fold, q<0.05) (Figure 2.4a). Although the enrichment 
fold changes for some of the bacterial species appear very high, their relative abundance 
in the whole microbial community could be low. This is due to the commonly used 
sampling normalization approach based on per million sequences to remove any bias due 
to varying sequencing depth (details in Methods). Overall, trends showed that 
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Bacteroidetes OTUs were increased in the RS4 group, leading to an overall lowering of 
the average Firmicutes-to-Bacteroidetes (F:B) ratio  in the RS4 group from 14.6 at 
baseline to 12.9, but increasing to 19.2 post CF diet (Figure 2.4b). The lower F:B ratio is 
frequently perceived as an indicator of a leaner phenotype, although the previously 
reported results are not always consistent [91]. Firmicutes and Bacteroidetes are two 
major phyla and the species composition within each may vary widely in a given subject. 
It is possible that both phyla include species that may be characteristic of a particular 
phenotype. Therefore, a species level composition may represent a body weight 
phenotype more precisely than a broad estimation of F:B ratio.   
 
Impact of RS4 on gut microbiota composition compared before and after RS4 
intervention 
Firmicutes species from Clostridium cluster XIVa account for almost 60% of the 
mucin-adhered microbiota [92]. A general observation was that species from Clostridial 
cluster XIVa, but not cluster IV, were enriched by RS4 supplementation of the diet. At 
the species level (Figure 2.4c), RS4 consumption increased the abundance of 
Bifidobacterium adolescentis (90.5 fold, q=0.087) and Parabacteroides distasonis 
(1180.2 fold, q<0.001) but not Ruminococcus bromii (−3.2 fold, q>0.05), 
Fecalibacterium prausnutzii (−1.2 fold, q>0.05), or Dorea formicigenerans (1.1 fold, 
q>0.05), which confirmed the previous report [24]. Novel observations include an RS4-
induced increase in Christensenella minuta abundance (119.7 fold, q=0.038, 97% query 
coverage, 88% identity and E<0.001 in NCBI-BLAST) as well as in several OTUs in the 
family Ruminococcaceae and genus Bacteroides. At the species level, Bacteroides ovatus 
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(37.6 fold, q=0.087), Ruminococcus lactaris (2866.7 fold, q<0.001), Eubacterium 
oxidoreducens (3.3x105 fold, q<0.001), Bacteroides xylanisolvens (47.8 fold, q=0.037), 
and Bacteroides acidifaciens (92.4 fold, q=0.038) were enriched after RS4 intervention.  
 
RS4 consumption altered fecal SCFAs linked to specific gut microbes  
Acetate was the most abundant SCFA, accounting for over 60% of total SCFAs 
before and after the interventions in both RS4 and CF groups. The individual proportions 
of the SCFAs, butyric (69.5%, p=0.03), propionic (50.2%), valeric (44.1%), isovaleric 
(20.3%), and hexanoic (19.2%) acids increased post intervention from baseline in the 
RS4 group (p<0.05, Figures 2.5 and 2.6a) but not in the CF group (data not shown). A 
24.6% decrease in isobutyric acid in the RS4 group was observed. A Pearson correlation 
analysis showed a potential link between significant changes in the gut microbiota 
composition induced by RS4 and altered SCFA levels (Figure 2.6b). Acetate and butyrate 
levels were correlated (p<0.05) with Ruminococcus lactaris (r=0.54) and Oscillospira 
spp. (r=0.41). Total SCFAs were correlated with the abundance of two species: 
Methanobrevibacter spp. (r=0.43) and Ruminococcus lactaris (r=0.52). Propionate and 
isobutyrate levels were linked to Methanobrevibacter spp. (r=0.65 and r=0.79, 
respectively), Eubacterium dolichum (r=0.42 and r=0.43, respectively), Christensenella 
minuta (r=0.39 and r=0.59, respectively), and Ruminococcus lactaris (r=0.59 and r=0.40, 
respectively), of which the latter two were increased by RS4 (Figure 2.4a, 2.4c, and 2.6b). 
Interestingly, these associations of SCFAs with specific gut microbiota were not observed 
after CF intervention (data not shown). To our knowledge, prior studies with RS4 have 
not reported significant SCFA changes in human fecal samples. 
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Impact of RS4 intervention on circulatory adipocytokines 
In obesity, macrophages infiltrate adipose tissue and secrete proinflammatory 
cytokines such as IL6 and TNF-α [93]. Also, adiponectin is released by adipocytes in the 
blood and has important roles in lipid and glucose metabolism [94]. Reduced adiponectin 
levels are associated with various aspects of metabolic dysfunction [95]. Compared with 
baseline, IL6 decreased by 38% (p=0.04), and adiponectin levels increased by 20% 
(p=0.002) in the RS4 group, while TNF-α did not change significantly. Both TNF-α and 
adiponectin concentrations were lower post RS4 diet compared with post CF diet (p=0.08 
and p=0.02 respectively, Table 2.3).  To our knowledge, this is the first report showing 
changes in adipocytokines, which help determine progression to cardiovascular 
aberrancies [95, 96], in response to RS4 intake in humans.  
 
Impact of RS4 consumption on body composition, lipids, and glucose metabolism 
Individuals had lower % body fat (p=0.05) and lower non-high density lipoprotein 
(non-HDL, p=0.003), HDL (p=0.005), and total cholesterol (TC, p<0.001) post RS4 
consumption compared with post CF consumption (Table 2.3). A trend was observed for 
lower waist circumference (p=0.06), glycosylated hemoglobin (HbA1C, p=0.08), and 
fasting blood glucose (p=0.09) following RS4 consumption compared with CF 
consumption. It is likely that response variation among participants to an RS4 diet 
contributed to these higher p-values. Varying responses to dietary interventions among 
individuals are frequently reported [97]. Changes in fasting glucose and HbA1C were 
more pronounced in this cohort (−8.6% and −1%, respectively) compared with the parent 
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cohort (−4.2% and no decrease, respectively). Attenuation of % body fat combined with a 
smaller waist circumference indicates a potential reduction in central obesity in these 
individuals. Although significant, these changes were modest, as measures of body 
composition do not change rapidly in adults and can take several months to years to show 
a larger change. Waist circumference, TC, HDL, and non-HDL were also reduced in the 
RS4 group compared with baseline (all, p<0.05). No significant effects of RS4 were 
observed on blood pressure or triglyceride levels in either group (Table 2.3). The average 
lipid and glycaemic profiles were apparently within normal limits, likely due to 
prescribed medication usage for various metabolic dysfunctions (Table 2.1).   
 
Inter-associations between gut bacteria and metabolic functions  
Multiple novel gut microbial associations with metabolic functions were observed 
post intervention in the RS4 group compared with the CF group (Figure 2.7). We propose 
that the associations detected post RS4 diet, but not post CF diet, could be induced by 
RS4. However, several associations were common to both groups, lacking specific 
response to RS4 enrichment. RS4-specific inverse correlations were observed between 
TC and the abundances of Bacteroides plebeius (r=−0.46), Blautia producta (r=−0.49), 
and Prevotella stercorea (r=−0.45; all, p<0.05). Although the abundances of 
Parabacteroides distasonis and Oscillospira spp. were enriched post RS4 compared with 
post CF intervention, their negative association with TC, low-density lipoprotein (LDL), 
and non-HDL were not RS4-specific (all, p<0.05).  In another instance, while RS4 did 
not significantly alter the abundance of Fecalibacterium prausnitzii, an RS4-specific 
negative correlations between this species and body mass index (BMI, r=−0.45) and % 
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body fat (r=−0.56) were observed (all, p<0.05). An RS4-specific correlation between 
adiponectin and Bacteroides ovatus (r=0.79, p<0.01), Bacteroides uniformis (r=0.56, 
p<0.05), and Bacteroides acidifaciens (r=0.82, p<0.001) was observed (Figure 2.7). RS4 
intake did not significantly enrich Methanobrevibacter spp. and Eubacterium dolichum, 
but these bacteria were correlated with weight and BMI (Figure 2.7) as well as with 
SCFA levels (Figure 2.6b) in an RS4-specific manner. Methanobrevibacter spp. 
(r=−0.45), Ruminococcus gnavus (r=−0.56), and Prevotella stercorea (r=−0.45) were 
negatively correlated with LDL (p<0.05), while Blautia producta (r=−0.44) and 
Prevotella stercorea (r=−0.50) were negatively associated with TC and non-HDL (all, 
p<0.05) in an RS4-specific way.  
 
Intra-association within gut microbes 
Little is known about how the relative abundance of one microbial species may 
influence the presence of another species within the gut ecosystem, particularly in 
response to RS4 consumption. To evaluate this question, we examined intra-association 
and clustering among those bacteria that showed RS4-specific association with SCFAs 
and metabolic features. Three Bacteroides species that showed a positive correlation with 
adiponectin and Prevotella stercorea, which associated with TC, LDL, and non-HDL, 
were clustered together (Figure 2.7 and 2.8). In general, a higher association within 
Bacteroidetes species or within Firmicutes species was observed, although there were 
exceptions. One example is Bacteroides plebius, which correlated with the Firmicutes 
member Blautia producta (r=0.98, p=<0.001), and both of these were negatively linked 
to RS4-induced changes in TC or non-HDL. Christensenella minuta tended to associate 
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with Ruminococcus lactaris (r=0.58, p=0.02), and both were enriched after RS4 
intervention. Both Christensenella minuta and Ruminococcus lactaris also clustered with 
Methanobrevibacter spp. and Eubacterium dolichum (both p<0.05), but not with 
Ruminococcus torques and Oscillospira spp., although all of them were associated with 
one or more SCFAs (2.6b and 2.8).   
 
Association among metabolic features 
Variation in response to RS4 among participants was observed, and the pattern is 
similar for various host metabolism parameters (response variation data not shown). This 
pattern may be due to the known link between high levels of circulating lipids and 
glucose with lower blood adiponectin levels [98] and the correlation of up-regulated IL6 
and tissue necrotic factor-α with the pro-inflammatory state in obesity [99]. The 
clustering of metabolic dysfunctions and CVD risk factors in adults has been observed in 
epidemiological studies and in the clinical setting [100]. In line with that, we observed 
consistent intra-associations among parameters of metabolic dysfunction within our data 
set independent of dietary changes (Figure 2.9). TC and non-HDL, but not HDL, 
correlated more closely with each other (r=0.95, p<0.001). Similar correlations were 
observed among various anthropometric measures, such as weight, BMI, and waist 
circumference, as well as fasting glucose (p<0.05). Fasting glucose correlated with IL6 
level (r=0.51, p=0.07), which in turn was associated with diastolic blood pressure (r=0.78, 
p<0.01), systolic blood pressure (r=0.52, p=0.07), and waist circumference (r=0.60, 
p=0.03). Triglyceride concentrations were positively associated with weight (r=0.82, 
p<0.001), waist circumference (r=0.60, p=0.03), and BMI (r=0.64, p=0.02), while 
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negatively correlated with HDL (r=−0.65, p=0.02) and adiponectin (r=−0.45, p=0.12) but 
had little apparent link with TC and LDL. 
 
2.5. Discussion   
Our present study provides for the first time a microbiome signature in response 
to RS4 consumption in subjects with MetS.  Among the comorbidities of MetS, 
numerous studies associated a dysbiosis with obesity and type 2 diabetes [101], but less is 
known about the role of the microbiota-diet interactions in hypercholesterolemia [102]. A 
handful of in vitro, animal, and healthy volunteer studies suggested that the microbiota 
affects lipid metabolism [103-105], but a clear understanding is lacking. Reduction in 
plasma TC and non-HDL and HDL cholesterol after RS4 consumption was consistently 
observed in the larger parent cohort [25] as well as in the present sub-cohort when 
compared with the control group and with baseline. In addition, a novel link between TC 
and non-HDL with three bacterial species was observed in an RS4-specific manner. The 
effect of an RS4 diet on Parabacteroides distasonis without any context of lipid 
metabolism was previously reported [24] and further confirmed by our results. 
Parabacteroides distasonis was augmented post-RS4 compared with the post-CF and 
baseline. This species showed a correlation with TC and non-HDL in both intervention 
groups and clustered with species belonging to both the Bacteroidetes and Firmicutes 
phyla. While RS4 also lowered HDL, such a reduction is not always associated with 
increased cardio-vascular disease risk, while lowering of TC and non-HDL, which 
includes LDL, remains critical [106].  
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Another novel RS4-induced microbial enrichment involved Christensenella 
minuta in the family Christensenellaceae, which was identified in human faeces only 
recently [107]. This species was reported as being heritable, based on host genetics, and 
abundant in healthy, lower-BMI individuals, and its addition reduced microbiome-
mediated weight gain in germ-free mice [108]. Christensenella minuta was enriched post 
RS4-diet compared with post CF-diet and the baseline, and correlated in an RS4-specific 
manner with higher propionate, isobutyrate, valerate, and isovalerate concentrations, 
similar to that of Methanobrevibacter spp. in the Methanobacteriaceae family. This result 
is in line with a previous report that this bacterium co-occurs with Methanobacteriaceaea 
members, and both together produce SCFAs [108]. Moreover, Christensenella minuta 
was reported to augment Oscillospira, a bacterium that was enriched and associated with 
higher isovarelate levels post-RS4 but not post-CF. However, contrary to a prior 
suggestion [108], our results present evidence that Christensenella minuta is amenable to 
dietary intervention. We also observed a positive correlation of this species with weight 
and BMI, which was, however, non-specific to RS4 intervention. Future investigations 
may address whether Christensenella minuta-mediated energy harvest from SCFAs is 
utilized differently by individuals with MetS than by the lean and healthy individuals 
involved in prior studies [107, 108].  
Complex carbohydrate or glycan availability is a major factor in shaping the gut 
microflora [109]. Since many of the starch-degrading enzymes are represented as a 
starch-utilization system (SUS) in ~20% of the genome of Bacteroidetes species [109-
111], enrichment  of Bacteroides ovatus and Parabacteroides distasonis after RS4 
intervention in this study was as expected. Further confirmation with  Carbohydrate-
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Active Enzymes (CAZy) database (http://www.cazy.org/) [112] supported that  
Bacteroidetes species are dominant starch-degrading bacteria after RS4 intervention. 
The strengths of this study include statistically significant observations of 
prebiotic RS4-induced changes across microbial composition, fecal SCFA levels, and 
host immunometabolic functions, all of which are relevant to the underlying physiology 
of individuals with pre-existing metabolic dysfunctions. Human dietary interventions 
conducted within natural settings and reporting statistically significant outcomes that are 
consistent across a broad range of metabolic health measures are rare [113]. One 
exploratory human intervention study attempted to show the prebiotic diet concept for 
combating obesity by undertaking a similar comprehensive investigation, but utilized a 
parallel design and a different kind of non-RS prebiotic diet. In that study, the changes in 
the microbiota and some metabolites, although not including SCFA, were observed, but 
without any concomitant improvement in metabolic functions [114]. This difference 
could be due to RS4 having a different prebiotic impact on such parameters or due to the 
crossover design of our study, which allowed each participant to serve as his/her own 
control, minimizing the influence of confounding variables on treatment effects. In 
addition, a stringent FDR at 0.05 helped minimize false positives for gut microbial 
changes. Furthermore, novel associations among host metabolic functions and species-
level composition of the gut microbiota were observed, many of which also coincided 
with intra-species clustering, indicating the possibility of a synergistic (within bacterial 
species) as well as super-system interactions (symbiotic host–microbe systems) linked 
with metabolic functions. However, we note that fecal SCFAs represent <5% of the total 
SCFAs that are typically excreted, while the major portion of SCFAs is efficiently 
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absorbed in the intestinal lumen [103]. Also microbial communities in fecal samples may 
potentially exclude gut residents that are not shed. Nevertheless, fecal specimens are the 
most practical samples obtained from a human dietary intervention study for assessing 
the gut microbiome.  
 
2.6. Conclusion 
In conclusion, this study provides evidence that dietary RS4 supplementation 
selectively changes the gut microbial and metabolite environment as well as associated 
host metabolic functions. To our knowledge, this is the first holistic study that 
investigated the effects of the fermentable fiber, RS4, on the gut microbial ecology, 
functional metabolites like SCFAs, and physiological responses in the host in one well-
designed study in a free living Caucasian cohort with signs of MetS. The findings support 
the perceived role of the microbiota–host interaction in nutritional therapies with 
important implications for dietary guidelines for individuals with metabolic disorders, a 
major public health concern of the present day. 
 
2.7. Future Directions 
1. To compare the gut microbial profiles from persons with or without MetS, which 
would help delineate the signature microbiome in MetS. 
2. To identify the responders and non-responders to RS4 in terms of some selected 
gut microbiota or SCFAs, or parameters. 
3. To identify the sources of health promoting metabolites, either from food, 
microbiota, or host itself. 
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Figures and Legends 
Figure 2.1. Study design  
(a) Time line of the placebo-controlled, crossover, dietary intervention with resistant 
starch (RS4) and control flour (CF). Stool and blood samples were collected before and 
after each treatment period (indicated by arrows). (b) Trial profile and numbers of 
participants in the study.  
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Figure 2.2.  Phylum-level gut microbial composition of participants at baseline 
Mean percentage of total bacteria in the major phyla (n=19).  
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Figure 2.3. Separation of the microbiome post intervention in RS4 and CF groups 
Two-dimensional principal coordinate analyses (PCoA) based on the weighted UniFrac 
distance between samples, given the abundance of 5,831 taxa present in at least one 
sample (n=19). Axes 1 and 2 explain 26% and 13% of the variation, respectively (p = 
0.01).   
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Figure 2.4. Differential gut microbial composition after RS4 intervention at the 
species level.  
(a) Relative abundance of bacterial species (log10 fold change) in the RS4 group 
compared with the CF group post intervention (n=19). Significant compositional 
variation between the two groups before the intervention was previously ruled out. (b) 
The Firmicutes/Bacteroidetes ratio after intervention (n=14). The dotted line represents 
this ratio at baseline. (c) Abundance of major bacterial species (log10 fold change) before 
and after RS4 treatment. #, the closest hit from the NCBI 16S rRNA database cross-
referenced with the OTU from the Greengenes database. *Adjusted p (q)≤ 0.05, **q≤0.01, 
***q≤0.001, § q≤0.09 (trend/approaching significance), n=19.  
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Figure 2.5. Representative chromatograms showing the overlay of retention times of 
butyl esters of SCFA fragment from standard and biological sample.  
Butyl esters of acetic acid (1), propionic acid (2), iso-butyric acid (3), butyric acid (4), 
iso-valeric acid (5), valeric acid (6), internal standard (7), and hxanoic acid (8). * 
represents the di-butyl ether as a side product of butylation that did not co-elute with the 
sample analytes. One of the collaborators, Dr. Ali Reza Fardin-Kia helped with technical 
and instrumental aspects of GC-MS analyses.  
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Figure 2.6. Effects of RS4 on fecal SCFAs  
(a) SCFA abundance before and after RS4 intervention (*p≤0.05, n=19).  (b) Positive 
correlation of six bacterial species with increased SCFA levels in an RS4-specific manner 
(p<0.05).  Pearson coefficients are shown on heat map. #, the closest hit from the NCBI 
16S rRNA database cross-referenced with the OTU from the Greengenes database. †, 
species either significantly enriched or approached significance in the RS4 group. One of 
the collaborators, Dr. Ali Reza Fardin-Kia and Robert Juenemann helped with technical 
and instrumental aspects of GC-MS analyses.  
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Figure 2.7. Associations between gut microbiota and host biological parameters 
after RS4 and CF interventions  
(a) Heat map showing Pearson’s r values (all, p<0.05). Black rectangular borders indicate 
an association present only post RS4 intervention. #, the closest hit from the NCBI 16S 
rRNA database cross-referenced with the OTU from the Greengenes database. †, species 
either significantly enriched or approached significance in the RS4 group, n=15.  
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Figure 2.8. Intra-associations within bacterial species that were correlated with 
metabolic functions or SCFAs in an RS4-specific manner  
Heat map showing Pearson’s r-values, corresponding to the size of the circle (n=19). The 
black border indicates clustering of species (*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, shown 
only in the upper triangle). #, the closest hit from the NCBI 16S rRNA database cross-
referenced with the OTU from the Greengenes database. †, species either significantly 
enriched or approached significance in the RS4 group.  
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Figure 2.9. Associations among host biological parameters in the RS4 group  
Heat map showing Pearson’s r-values, corresponding to the size of the circle (n=13, *p ≤ 
0.05, **p ≤ 0.01, ***p ≤ 0.001). 
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Table 2.1.  Baseline characteristics of 20 participants 
 
 
 
 
 
 
 
 
 
 
 
 
n: number of individuals 
BMI: body mass index 
  
Criteria n 
Age (years)  
<50 5 
≥50 15 
  
BMI  
<30 5 
≥30 15 
  
Gender  
Male 8 
Female 12 
  
Medication for  
No medication 8 
Type 2 diabetes 4 
Heart diseases 2 
Blood pressure 11 
Fiber supplement 2 
Probiotic 
supplement 
1 
Digestive support 3 
Cholesterol lowering 5 
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Table 2.2.  Estimated nutrients intake at baseline and at the end of intervention 
periodsa 
 a Data are Least Square Means+SEM adjusting for age, sex, season, colony and baseline 
value analysed by linear mixed model; n=18-20 due to missing data points. 
BL: baseline; CF: control flour; RS4: resistant starch type 4  
One of the collaborators, Dr. Lacey McCormack helped with data analyses 
  
Nutrients BL Post CF Post RS4 p: post CF  vs post RS4 
Caloric intake (kcal/d) 1774±154 1528±121 1716±128 NS 
Protein (g/d) 76±7 72±5 62±4 NS 
Carbohydrate (g/d) 218±21 220±19 212±18 NS 
Total fat (g/d) 68±7 60±5 53±5 NS 
Cholesterol (mg/d) 415±40 442±38 407±35 NS 
Saturated fat (g/d) 25±3 22±2 21±2 NS 
Monounsaturated fat (g/d) 26±3 22±2 19±2 NS 
Polyunsaturated fat (g/d) 10±1 9±1 7±1 NS 
Total dietary fiber (g/d) 18±2 16±2 27±2 <0.001 
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Table 2.3.  Means of biological parameters at baseline and at the end of intervention 
periodsa 
a Data are Least Square Means+SEM adjusting for age, sex, season, colony and 
baseline values.  
b Geometric mean and confidence interval are given for log-transformed 
triglyceride endpoints.   
One of the collaborators, Dr. Lacey McCormack helped with data analyses
 BL Post CF Post RS4 
p: Post 
CF 
vs Post 
RS4 
p: BL 
vs post 
RS4 
Anthropometrics      
Weight (kg) 90.9±3.4 91.0±0.4 91.6±0.4 NS NS 
BMI (kg/m2) 32.8±1.1 32.8±0.1 32.7±0.1 NS NS 
Waist (cm) 109.0±2.8 108.8±0.9 106.6±0.9 0.06 0.02 
Systolic BP (mm Hg) 135.0±3.9 134.6±3.5 137.5±3.5 NS NS 
Diastolic BP (mm 
Hg) 
73.7±2.2 68.6±2.0 73.3±2.0 NS NS 
% Body Fat 37.0±1.8 37.7±0.3 37.3±0.3 0.05 NS 
Fat-free mass (kg) 58.8±3.0 58.8±0.3 58.9±0.3 NS NS 
Glycemic Variables 
(mg/dL) 
     
Fasting glucose 106.5±4.1 111.5±4.2 101.9±4.3 0.09 NS 
Postprandial glucose 113.5±11.8 124.3±7.3 114.3±7.5 NS NS 
HbA1C (% of total 
Hb) 
5.89±0.3 5.81±0.1 5.75±0.1 0.08 NS 
Lipid Variables 
(mg/dL) 
     
Total cholesterol 196.6±11.6 192.8±4.6 187.8± .9 <0.001 0.01 
HDL cholesterol 43.6±3.3 44.1±1.3 39.8±1.3 <0.01 0.001 
LDL cholesterol 122.7±10.1 117.4±5.6 118.0±6.1 0.06 0.06 
NonHDL cholesterol 153.1±11.8 148.4±4.6 147.5±4.9 <0.01 0.03 
TC/HDL (ratio) 5.0±0.5 4.7±0.2 5.1±0.2 NS NS 
Triglyceridesb 161.5±19.9 144 (119-
176) 
138 (110-
173) 
NS NS 
      
Blood Biomarkers      
IL6 (pg/mL) 1.3±0.2 1.0±0.2 0.8±0.2 NS 0.04 
TNF-α (pg/mL) 7.9±4.2 9.9±1.2 6.0±1.3 0.08 NS 
Adiponectin (µg/mL) 8.3±1.5 10.8±0.4 10.0±0.4 0.02 <0.01 
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CHAPTER 3 . DIETARY RESISTANT STARCH TYPE 4-ASSOCIATED 
BUTYRATE MODULATES LYSINE 27 TRIMETHYLATION OF HISTONE 3 IN 
THE PROMOTER OF NUCLEAR FACTOR-KAPPA-B1 IN INTESTINAL 
EPITHELIUM 
 
Related publication: Liu, Y* and Upadhyaya, B*. et al. Dietary resistant starch type 4-
associated butyrate modulates lysine 27 trimethylation of histone 3 in the promoter of 
nuclear factor-kappa-B1 in intestinal epithelium, Food & Function (2016) DOI: 
10.1039/C6FO00856A [Accepted manuscript, *Equal contributors] 
 
3.1. Abstract 
Indigestible resistant starches (RS) are substrates for gut-microbial metabolism 
and have been shown to attenuate intestinal inflammation but the supporting evidence is 
inconsistent and lacks mechanistic explanation. We have recently reported dietary RS 
type 4 (RS4) induced improvements in immunometabolic functions in humans and a 
concomitant increase in butyrogenic gut-bacteria.  Since inflammation is a key 
component in metabolic diseases, here we investigated the effects of RS4-derived 
butyrate on epigenetic repression of pro-inflammatory genes in vivo and in vitro. RS4-fed 
mice, compared to the control-diet group, had higher cecal butyrate and increased tri-
methylation of lysine 27 on histone 3 (H3K27me3) in the promoter of nuclear factor-
kappa-B1 (NFκB1) in the intestinal tissue. The H3K27me3-enrichment inversely 
correlated with concentration dependent down-regulation of NFκB1 in sodium butyrate 
treated human intestinal cells. Two additional inflammatory genes were attenuated by 
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sodium butyrate, but were not linked with H3K27me3 changes. This proof-of-concept 
exploratory study presents a new opportunity for studying underlying H3K27me3 and 
other methylation modifying mechanisms linked to RS4 biological activity.  
Keywords: resistant starch type 4, sodium butyrate, H3K27me3, short chain fatty 
acid, inflammation 
 
3.2. Introduction 
Intestinal gut microbiota utilizes prebiotic fibers like resistant starch (RS) as a 
substrate to produce short chain fatty acids (SCFAs) that is proposed to play an anti-
inflammatory role in the maintenance of intestinal immune homeostasis [115], although 
conflicting results exist [116]. Consumption of a fiber-rich diet is nevertheless considered 
beneficial in several diseases such as obesity, inflammatory bowel disease, and metabolic 
syndrome (MetS), all of which are associated with gut microbial dysbiosis and 
dysregulated mucosal immunity [117]. In particular, inflammation is considered as a key 
pathophysiological player in MetS [118]. We previously reported that consuming RS type 
4-(RS4)-enriched flour (30% v/v) as part of a routine communal diet has significant 
cholesterol lowering effects in healthy as well as in subjects with signs of MetS [25]. A 
retrospective follow-up of the study showed that participants who consumed RS4 had 
increased fecal SCFAs, particularly butyrate, in conjunction with increased butyrogenic 
microbiota in fecal samples [119]. Butyrate, as a major and representative form of SCFAs, 
has both trophic and bioactive functions on host cells by correcting the altered ratio of gut 
bacteria and protecting against the potential pro-inflammatory molecules [35]. It has been 
reported that increasing large-bowel butyrate supply has the potential to promote colonic 
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integrity and lower colonocyte risk [120]. In that context this proof-of-concept study 
aimed to explore if RS4 (chemically modified RS), particularly through butyrate 
production, epigenetically regulates inflammatory gene expression in the gut. 
Histone modifications, especially histone acetylation and methylation, play a 
dominant role in epigenomic regulation of gene expression [121]. Butyrate is well known 
as a histone deacetylase (HDAC) inhibitor that alters chromatin structure through histone 
acetylation, which in turn affects target gene expression associated with the maintenance 
of gut immune homeostasis [115, 122]. Butyrate’s anti-inflammatory activities [115] 
result from both HDAC dependent and independent inhibition of transcription factor 
nuclear factor kappa B (NFκB) [123, 124] as well as suppression of the downstream pro-
inflammatory chemokines and cytokines [125, 126]. However, knowledge is limited 
regarding the role of butyrate in modulation of histone tail methylation.  Of particular 
interest, in the context of inflammatory gene expression down-regulation, is the 
trimethylation of H3 at lysine 27 (H3K27me3), an important and well-studied 
modification that is frequently associated with transcriptional repression and gene 
silencing [59, 127]. 
In the present study, the wheat-derived cross-linked RS4 is used which has been 
thought to be effective in attenuation in postprandial glucose and insulin levels in humans 
[72]. Since RS4 is insoluble, we first examined the in vitro effects of sodium butyrate 
(NaBu) on H3K27me3 enrichment of gene promoters in conjunction with mRNA and 
protein expression of selected inflammatory markers in a human intestinal epithelial cell 
line, followed by a validation of RS4-induced butyrate production and a concomitant 
H3K27me3 modifying effects in vivo in mouse colon tissue. Of the three selected 
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inflammatory markers studied, a transcriptional factor NFκB1, which belongs to the 
NFκB family of transcription factors, plays a central role in inflammatory signaling [128]. 
The remaining two inflammatory mediators represented a chemokine (C-C motif) ligand 
2 (CCL2) that regulates migration and infiltration of monocytes/macrophages [125], and 
a T-helper type 2 (Th-2) cytokine interleukin-10 (IL-10), which diminishes the activity of 
Th-1 cytokine interferon gamma (IFNγ) and monocyte [126].  
 
3.3. Materials and Methods 
Materials 
Dulbecco’s Modified Eagle’s Medium (DMEM) with 4 mM L-glutamine and 4.5 
g/l glucose was purchased from HyClone (Logan, UT), fetal bovine serum (FBS), and 
trypLE were purchased from Invitrogen Gibco (Grand Island, NY). Dimethyl sulphoxide 
(DMSO), lipo-polysaccharide (LPS, from Escherichia coli, O55:B5), 
penicillin/streptomycin, hydrogen chloride-1-butanol, and NaBu (sodium salt of butyrate) 
were purchased from Sigma-Aldrich (St. Louis, MO), while IFNγ was purchased from 
R&D Systems (McKinley, NB). For western blot, antibody against β-actin was purchased 
from Santa Cruz Biotechnology (Santa Cruz, CA), antibody against NFκB1 was 
purchased from Millipore (Billerica, MA), and Dylight 800 anti-rabbit secondary 
antibody was purchased from Li-Cor Biosciences (Lincoln, NE). Anti-trimethyl-Histone 
H3 Lys27 and rabbit IgG negative control antibodies used for chromatin immuno-
precipitation (ChIP) assay were purchased from Upstate Biotechnology (Billerica, MA). 
Enzymes used for ChIP assay, Micrococcal Nuclease (MNase) and Proteinase K were 
purchased from Cell Signaling (Beverly, MA) and Pierce (Thermo Scientific, Rockford, 
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IL), respectively. All other ChIP assay chemicals, aprotinin, DL-1, 4-Dithiothreitol 
(DTT), Nonidet-P40 (NP-40) were purchased from Thermo Scientific (Rockford, IL), 
while protein-A sepharose and sucrose were purchased from Sigma-Aldrich (St. Louis, 
MO). ChIP incubation buffer was purchased from Abcam (Cambridge, MA) and DNA 
purifying slurry for ChIP-graded DNA purification was purchased from Diagenode 
(Denville, NJ). 2-Ethylbutyric acid ( 99%) and  1-butanol (99.9%) used as internal 
standard in gas chromatography- mass spectrometry (GC-MS) were purchased from 
Acros Organics (Mullica Hill, NJ) and Alfa Aesar (Ward Hill, MA), respectively. Hexane 
(>97.0%) and sodium sulphate (granular, anhydrous, >99.0%) were purchased from 
Fisher Scientific (Hampton, NH), while the inert helium gas was purchased from 
Matheson (Sioux Falls, SD). Oligonucleotides were synthesized by IDT DNA Inc. 
(Coralville, IA). 
 
Cell culture and treatment 
All in vitro assays were conducted in human colon cancer cell line, SW480 (CCL-
228, ATCC, Manassas, VA). Cells were grown in DMEM supplemented with 10% FBS, 
1% penicillin (25 U/ml)/streptomycin (25 µg/ml) in a 95% air/5% CO2-humidified 
atmosphere at 37 0C. This cell line was cultured as previously described [59]. Briefly, 
SW480 cells were pre-treated with IFNγ (10 ng/ml) or control medium for 12 h, treated 
with NaBu or DMEM (as a negative control) for 5 h and then stimulated with LPS (10 
ng/ml) for 4 h. For every experiment, one positive control (cells treated with LPS) and 
one negative control (cells treated without LPS or any NaBu treatments) were included. 
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Two replicates were used for both the treatments and controls. LPS and NaBu were 
reconstituted in DMEM. 
 
Total RNA extraction, cDNA synthesis and quantitative polymerase chain reaction 
(qPCR) 
Total RNA was extracted from cells using TRIzol reagent (Invitrogen, Grand 
Island, NY), following the manufacturer's instructions. RNA was quantified 
spectrophotometrically by absorption measurements at 260 nm and 280 nm using the 
NanoDrop system (NanoDrop Technologies, Wilmington, DE). RNA was then treated 
with DNase I (Invitrogen, Grand Island, NY), following the manufacturer's guidelines to 
remove any traces of DNA contamination. The cDNAs were synthesized using 3 µg of 
RNA for each sample using the High-Capacity cDNA Reverse Transcription (RT) Kit 
(Invitrogen, Grand Island, NY), following the manufacturers’ protocol. Two microliters 
of each diluted sample was added to 0.5 µl of gene-specific primers and 12.5 µl of Power 
SYBR green PCR master mix (Invitrogen, Grand Island, NY), and the final volume was 
brought to 25 µl by adding sterile distilled water. PCR amplifications were performed on 
a MX3005P system (Stratagene, San Diego, CA) using one cycle at 50 0C for 2 min, one 
cycle of 95 0C for 10 min, 40 cycles of 15 s at 95 0C and 1 min at 60 0C, and the last cycle 
with 95 0C for 1 min, 55 0C for 30 s, and 95 0C for 30 s. RNA extraction, purification, 
cDNA synthesis and RT-PCR were performed as previously described [129] in duplicate. 
Gene-specific primers used in the current study are described in Table 1. Calculations of 
relative gene expression levels were performed using the 2-ΔΔCt method [130]. The mRNA 
levels were normalized to a housekeeping gene, glyceraldehyde-3-phosphate 
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dehydrogenase (GAPDH), and expressed as a fold change relative to positive-control 
cells. 
 
Western blot analysis 
For immunoblot analyses, IFNγ-primed NaBu-treated human intestinal epithelial 
cells were activated with LPS for 4 h and harvested using RIPA lysis buffer (20 mM Tris-
HCl pH 7.5, 150 mM NaCl, 1 mM Na2EDTA, 1 mM EGTA, 1% NP-40, 1% sodium 
deoxycholate, 2.5 mM sodium pyrophosphate, 1 mM β-glycerophosphate, 1 mM Na3VO4, 
1 µg/ml leupeptin). The Pierce BCA Protein Assay kit (Thermo Scientific, Rockford, IL) 
was used to determine protein concentration. Proteins (35-50 µg/lane) were separated by 
12% SDS-PAGE and the products were electrotransferred to polyvinyldene difluoride 
membranes (Thermo Scientific, Rockford, IL). The membranes were blocked with 5% 
skim milk for 1 h, and incubated with primary antibodies at 4 0C overnight (NFκB 
p105/p50). On the next day, membranes were incubated with Dylight 800 anti-rabbit 
secondary antibody (Li-Cor Biosciences, Lincoln, NE) for 1 h, and washed 3 times in 
PBS/T (0.1% Tween20 in PBS) all at room temperature. After rinsing in PBS/T, blots 
were imaged and quantitatively analyzed using an Odyssey infrared imaging system (Li-
Cor, Lincoln, NE). A loading control protein, β-actin, was used to calculate the relative 
expression of NFκB p105 and p50 subunits. 
 
Native ChIP assay in cell culture 
ChIP assay was performed as we previously described [59]. Briefly, cells were 
lysed by suspending in a sequence of lytic and purification buffers. DNA fragments of 
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300-800 bp long were obtained by treating the nuclear pellet, obtained from lytic buffers, 
with MNase (Cell Signaling, Beverly, MA) in digestion buffer for 6 min. DNA fragments 
were immunoprecipitated with specific antibodies (anti-trimethyl-Histone H3 Lys27 and 
rabbit IgG) at 4 0C overnight. Immunoprecipitated DNA fragments were extracted using 
protein-A sepharose (Sigma-Aldrich, St. Louis, MO) and purified using DNA purifying 
slurry (Diagenode, Denville, NJ). The amount of purified DNA was estimated by 
nanodrop of 200 ng purified DNA template using SYBR green chemistry as described in 
RT-qPCR quantification section. Promoter-specific primers used in the current study are 
described in Table 1. Calculations are expressed as a percentage of the input DNA.  
 
Animal housing, diet and tissue collection 
All in vivo procedures were approved and conducted following the Institutional 
Animal Care and Use Committee (IACUC) of South Dakota State University guidelines. 
Six-week old male KK.Cg-Ay/a (Jackson Laboratories, Bar Harbor, ME) mice were 
grouped at random to consume either RS4 or control diets. To avoid confounding effects 
of sex on weight gain, which was a measurable outcome for the study, only male mice 
were considered. Also, this study was conducted prior to the implementation of federal 
policy for considering both male and female sexes in biomedical experiments (NOT-OD-
15-102). Mice were caged in groups of three in a laboratory animal facility at an ambient 
temperature of 24-26 0C with 12-h light/dark cycle. During the first 3 weeks mice were 
allowed to acclimatize while consuming standard rodent chow, LabDiet® 5001 (LabDiet, 
St. Louis, MO). Animals were then switched to experimental diets (LabDiet, St. Louis, 
MO) formulated based on AIN 93 [131] either with 20% RS4 or control diet (CD).  
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Detailed composition of experimental diets is provided in Table 2. Mice were provided 
the experimental diets and water ad libitum for 12 weeks. Following CO2 euthanasia, 
colon tissues and cecum samples were immediately collected, snap frozen in liquid 
nitrogen and stored at -80 0C until further use. 
 
Determination of cecal weight and butyrate analyses 
Cecal tissues were weighed and pooled together (>500 mg in total weight) to 
represent one sample and vortexed for 1 min with 1 ml of internal standard (2-
ethylbutyric acid in 1-butanol, 0.25 mg/ml). 0.5 ml of hexane (organic solvent) and 2 ml 
of HCl-1-butanol (derivatizing agent) were then added to each sample followed by an 
additional 1 min vortexing and 5 min sonication prior to being purged with an inert 
helium gas. The tubes were immediately closed and each sealed container was incubated 
in water bath at 60 0C overnight in order to catalyze the derivatization of butyrate analyte. 
Upon being cooled to room temperature, 1.5 ml of additional hexane and 15 ml of 
deionized water were added. Samples were mixed by vortexing 1 min following each 
addition and then centrifuged at 3000 g for 2 min. The top organic layer (~2 ml) was 
transferred into a 5 ml graduated vial before blowing down with helium to one-fourth of 
the volume, thereby increasing the final concentration of internal standard from 0.25 
mg/ml to 1 mg/ml. Finally, each sample was transferred into a sampling vial containing a 
150 µl insert and ~10 mg of anhydrous sodium sulphate was added to remove the water 
content before running into the GC-MS.  
SCFAs were derivatized to obtain the corresponding butyl-esters (SCFABE) prior 
to their gas chromatography (Agilent 7890A, Agilent Technologies, Wilmington, DE) 
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and mass spectrometry (5977A MSD, Agilent Technologies, Wilmington, DE, USA) 
using HP-5MS UI capillary column (30 m x 0.25mm, 0.2 µm thickness, Agilent, 
Wilmington, DE, USA). Using hydrogen as carrier gas at a constant flow of 1.9 mL/min, 
a typical injection volume (1 µl) was injected in the split mode (1:10). The separation of 
SCFABE was achieved using an oven temperature program as follow: initial elution 
temperature of 55 0C for 4 min, an increase by 5 0C/min to 120 0C followed by 20 0C/min 
to 220 0C for 10 min. The selective mass detector was operated in the ‘single ion 
monitoring and scan’ (SIM/Scan) mode with the source temperature (150 0C) and the 
electron energy (70 eV). The abundance of butyrate analyte was identified by acquiring 
ions of a specific m/z value.  Finally, the data were analyzed and expressed as a unit of 
mg/g of cecal tissues used. 
 
Native ChIP assay in mouse colon tissues 
Colon tissues were collected from mice immediately after sacrifice, snap-frozen 
in liquid nitrogen and stored at -80 0C. On the day of assay, around 0.2 g of colon tissues 
were rinsed in cold PBS and homogenized on ice in a pre-chilled tube with 1 ml of ice-
cold Buffer 1 (0.06 M KCL, 15 mM NaCl, 5 mM MgCl2, 15 mM Tris-HCl pH 7.4-7.6, 
0.1 mM EGTA, 0.3 M sucrose, 180 µg aprotinin, 5 mM sodium butyrate, 0.1 mM PMSF, 
0.5 mM DTT), until the homogenate was free of clumps. The homogenate was then 
filtered through four layers of muslin cheesecloth, pre-autoclaved and pre-moistened with 
Buffer 1. The filtered cells were treated in the same way as described in the Native ChIP 
assay in cell culture section. Promoter methylation of genes of interest was determined in 
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mice fed RS4 or CD. Promoter-specific primers used in the current study are described in 
Table 1. 
 
Statistical analysis 
Data are expressed as mean ± SEM. One-way analysis of variance (ANOVA) was 
used to determine the significance between groups followed by the post-ANOVA 
Dunnett test. Intergroup comparisons in Western blot, ChIP assay in mouse colon tissues 
and for SCFAs in mouse cecal tissues were determined using Student’s t-test. A bivariate 
analysis was carried out using correlation coefficient method and presented as Pearson’s r. 
The significance of each treatment was interpreted by comparison with the appropriate 
control, as described under specific methods. Experiments were repeated at least three 
times. A probability (p) value of 0.05 or less was considered to be significant. 
 
3.4 Results 
NaBu attenuates expression of inﬂammatory mediators in a concentration 
dependent manner in intestinal epithelial cells 
LPS stimulated the production of pro-inflammatory mediators in IFNγ-primed 
human intestinal epithelial cells. In the cells treated with NaBu, compared to the positive 
control cells treated with LPS alone, we observed a concentration-dependent mRNA 
attenuation of CCL2 and NFκB1 (Figure 3.1a). The highest concentration of NaBu tested 
(1.25 mM) showed the strongest attenuation, lowering the relative mRNA expression of 
CCL2 and NFκB1 by 90% and 63%, respectively (both p < 0.001).  We also observed the 
similar effects in case of cytokine IL-10, where NaBu (1.25 mM) inhibited IL-10 mRNA 
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by 78% (p < 0.001, Figure 3.1a).  The untreated cells that served as negative control 
showed the highest level of IL-10, indicating the potential anti-inflammatory role of IL-
10 in the absence of a strong immune challenge by LPS (Figure 3.1a). However, it is 
possible that IL-10 gained a pro-inflammatory characteristics when primed with IFNγ 
prior to LPS induction as was observed by Sharif et al [132] and hence subsequently 
responded to NaBu in a similar manner to that of the other two pro-inflammatory 
mediators. This point is further elaborated in the “discussion” section. 
 
NaBu enriched H3K27me3 in the promoter of NFκB1in intestinal epithelial cells 
For ChIP assay we chose the highest dose (1.25 mM) of NaBu due to its most 
suppressive effects as observed for the gene expression data (Figure 3.1a). Compared 
with a positive control (Figure 3.1b), we observed the enrichment of H3K27me3 on the 
promoter region of NFκB1 (0.47 ± 0.23% vs 1.28 ± 0.08%, p < 0.05).  The H3K27me3 
enrichment pattern was not clear for the IL-10 promoter, possibly due to high inter-
sample variation.  For CCL2, a similar enrichment pattern to that of NFκB1 was absent, 
indicating the possibility of another gene regulatory mechanism influencing its mRNA 
downregulation (Figure 3.1a). Since CCL2 is a downstream effector of NFκB signaling 
[133], it is possible that the mRNA suppression of CCL2 is due to inhibition of NFκB1. 
 
Concentration-dependent suppression of NFκB1 protein and mRNA by NaBu 
inversely correlated with concentration-dependent enrichment of H3K27me3 in the 
NFκB1 promoter  
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We further examined the concentration-dependent effects of NaBu on NFκB1 
mRNA and protein downregulations simultaneously with the determination of a 
concentration-dependent H3K27me3 enrichment on NFκB1 promoter region. As shown 
in Figure 3.2a, the protein expression of p105 as well as the active p50 subunits of 
NFκB1 showed a concentration-dependent attenuation (p < 0.05) in response to NaBu in 
the IFNγ-primed and LPS-induced human intestinal epithelial cells. Interestingly, the 
relative protein expressions of both the sub units dropped close to the level of the 
negative control when treated with the 1.25 mM NaBu (p105: 0.77 ± 0.03 vs 0.81 ± 0.08 
folds and p50: 0.53 ± 0.15 vs 0.41 ± 0.13 folds). The suppression of both the subunits 
also negatively correlated with a simultaneous concentration-dependent upregulation of 
H3K27me3 modifications on the promoter region of NFκB1 (Figures 3.2b and 3.2c) 
(p105: Pearson’s r = -0.98, p = 0.022 and p50: Pearson’s r = -0.97, p = 0.025). Further, 
NaBu-associated H3K27me3 enrichment of NFκB1 promoter also inversely correlated 
with the relative NFκB1 mRNA expressions (Pearson’s r = -0.95, p = 0.045, Figures 3.1a, 
3.2b, and 3.2c). 
 
Body mass and food intake in mice study 
We have previously reported that RS4-enriched diet may be effective for reducing 
pathophysiological consequences in humans with MetS [25]. Since KK.Cg-Ay/a mice 
develops hyperglycemia, hyperinsulinemia, glucose intolerance and obesity by eight 
weeks of age, we in this study utilized KK.Cg-Ay/a mouse model to mimic age-related 
MetS in humans [134], evaluating the effects of RS4 intake on butyrate production in the 
cecum and butyrate-associated epigenetic regulation of inflammatory genes in the 
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intestinal tissue.  Since RS4 is a stealth ingredient [135], we incorporated RS4 in the 
mouse chow (20% v/v) and adjusted the CD to make it isocaloric with the addition of 
cellulose (Table 3.2). At the end of the 12-week feeding study, the cumulative food 
intake in RS4 group was around 35% higher when compared to that of CD group (560 ± 
22 g vs 415 ± 26 g, p = 0.004, Figure 3.3a). However, the cumulative body weight 
increases in both groups were similar during the 12-week period (Figure 3.3b), 
suggesting a possible higher metabolic efficiency of RS4 diet than that of the control diet. 
 
Cecal butyrate increased after RS4 intake in mice (butyrogenic effect of RS4) 
We have observed increased fecal butyrate levels post RS4 consumption in 
humans with MetS [119], which was expected due to RS4 being a non-digestible 
fermentable fiber [25]. However fecal SCFAs represent <5% of the total SCFAs while 
the majority of SCFAs are efficiently absorbed in the intestinal lumen [103]. In contrast, 
the cecum butyrate concentrations from a MetS mouse model may represent a higher 
proportion of the SCFAs produced in the gut.  The mice group receiving RS4 showed a 
trend for higher cecal weight compared to that of the CD group (322 ± 76 mg vs 135 ± 5 
mg, p = 0.07, Figure 3.4a), which is in line with a previous report where fermentation of 
RS type 2 and RS type 3 increased the cecal weight in mice [136].  Using these cecal 
samples, GC-MS analyses showed that butyrate concentration was about two-fold higher 
(0.81 ± 0.12 mg/g vs 0.39 ± 0.05 mg/g, p = 0.036) in the RS4 group than the CD group 
(Figure 3.4a). 
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Dietary RS4 intake enriched H3K27me3 in the promoter region of NFκB1 in mouse 
intestinal tissue 
After observing NaBu-mediated inhibition of histone modifications in vitro, we 
sought to examine the similar effects in the colon tissue from KK.Cg-Ay/a mice fed with 
20% RS4 for 12 weeks. ChIP assay revealed enrichment of H3K27me3 modification on 
the promoter region of NFκB1 (1.4 fold, p = 0.01) after RS4 intervention compared with 
CD (Figure 3.4b). This result supports the concept that feeding a butyrogenic dietary 
fermentable fiber, such as RS4, enriches the epigenetic repressive mark (H3K27me3), 
potentially contributing to the amelioration of the gut inflammation, a key factor 
underlying many chronic disorders including MetS. 
 
3.5. Discussion 
Supplementation of diets with prebiotic fibers for potential mitigation of pro-
inflammatory state in the context of chronic diseases, is an attractive area in public health 
research [117].  It was particularly proposed that the inhibition of inflammatory 
mediators through dietary enhancement of intestinal butyrate production has tremendous 
implications in the context of managing obesity-related metabolic diseases [137]. To our 
knowledge, this is the first report that dietary RS4 induced promoter-specific changes in 
the H3K27me3 enrichment in vivo likely by the way of increased colonic butyrate 
production. The in vitro observations further confirmed a concentration dependent 
repression of both NFκB1 mRNA and protein levels in response to NaBu with a 
concomitant enrichment in H3K27me3 levels.  
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Dietary fibers, which are otherwise indigestible to humans, undergo microbial 
fermentation in the hind-gut, particularly in the colon [138].  The colon is considered a 
metabolic organ where the mucosal epithelia absorb topical nutrients, such as SCFAs 
which play an important role in modulating gut immune system [139]. The gut 
microbiota is an essential component in the colonic microenvironment and an altered gut 
microbial composition or dysbiosis plays a critical role in the pathogenesis of intestinal as 
well as extra-intestinal diseases [140]. Butyrate acts as an energy source by epithelial 
cells [35] and inhibits genetic mutation [120] and oncogenic microRNA expression [141] 
in rectal biopsies associated diet-induced manipulation. In addition, in vivo research has 
investigated the anti-inflammatory role of SCFAs in regulating colonic regulatory T cells 
(cTReg cells) in mice [142, 143]. Butyrate increases the expression of FOXP3, a 
transcription factor functioning in intestinal inflammation, by increasing activity of 
histone acetylation in its promoter and enhancer region [142, 144] and consequences 
downregulation of pro-inflammatory mediators [145]. As we [119] and others [24] have 
observed that RS4 mediates the modulation of butyrogenic gut microbiota, we 
hypothesized that the observed immunomodulatory effects of RS4 in humans are at least 
partially derived from the anti-inflammatory mechanisms of butyrate that is produced 
after microbial fermentation of the dietary RS4.  To minimize use of animals, we first 
examined our hypothesis in an in vitro setting using a human intestinal cell line but since 
RS4 is insoluble [28, 146], we used sodium butyrate for the in vitro tests.   
The cytokine IL-10 is predominantly anti-inﬂammatory in nature that suppresses 
the dendritic and macrophage cell functions [147]. The IL-10 may, however, acquire pro-
inﬂammatory properties in inflammatory settings like endotoxemia, autoimmune diseases, 
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and graft transplantations [148-150]. The balance between pro- and anti-inﬂammatory 
activities of IL-10 is regulated by type I IFN [132]. Priming with type I IFNs (IFNα or 
IFNβ ) also leads to enhanced cellular responsiveness to IFNγ [151], the latter acting as 
an enhancer of cellular responsiveness to LPS through the toll-like receptor 4 signaling 
pathway in human intestinal epithelial cells, including SW480 [152]. Therefore, in our 
study, it is possible that IL-10 showed a pro-inflammatory nature as the human intestinal 
epithelial cells were primed with IFNγ  (10 ng/ mL) and stimulated with the LPS (10 ng/ 
ml), following Suzuki et al. [152]. Our results are also in line with the report of Saemann 
et al. that showed NaBu exerts its IL-10 enhancing properties only under the dose of 0.25 
mM, while inhibits IL-10 beyond the concentration of 0.25 mM [153]. This finding 
further supports our observation of IL-10 inhibition by NaBu at the concentration range 
of 0.31 to 1.25 mM. Also of interest is that the normal physiologic level of SCFAs in 
portal blood is (0.38 ± 0.07 mM) [154], signifying the concentrations used in our study 
are likely within the physiologically relevant range. 
Although congenic, age-matched, and randomized mice were supplied with 
isocaloric control diet, the cumulative food intake was consistently higher in the RS4 
group. It is possible that palatability of RS4 and cellulose were different with RS4, 
imparting minimal alteration of the physicochemical and organoleptic properties of the 
final food products [28], the mouse chow in this case. Interestingly, in spite of higher 
food intake, but with expected similar basal metabolic rate and physical activity, the mice 
in the RS4 group did not have a significantly higher weight gain by the end of twelfth 
week. This is consistent with the previous findings by Gao et al., [27] where butyrate 
supplemented mice consumed higher feed intake and showed higher lean mass but lower 
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fat mass, thus preventing diet-induced insulin resistance and obesity through more energy 
expenditure. This is the limitation of our study that we could not examine the body mass 
composition in the mice under study. In addition, the dietary fibers may also slow down 
the digestibility of protein and fats in diets, thereby decreasing the metabolizable energy 
content [155]. Since we also previously reported that RS4 consumption improves body 
composition of humans [25], the current study further corroborates the previous findings 
in KK.Cg-Ay/a mice and supports the suitability of this mouse model for age-related 
MetS in humans as proposed by Kennedy et al [134].  
The novelty of this research lies in the investigation of epigenetic mechanisms of 
butyrate on H3K27me3-enrichment that inversely correlated with concentration 
dependent down-regulation of a transcription factor NFκB1, which elegantly 
substantiates our previous findings of health promoting [25] and butyrogenic effects of 
RS4 [119]. Hence, RS4 and its derivative, butyrate, possesses promising clinical 
implications in the management of cardio-metabolic diseases in humans. 
 
3.6. Conclusions 
This exploratory study introduces a proof-of-concept that RS4 and its bacterial 
fermentation metabolite, butyrate, may function as an H3K27me3 modulator in 
conjunction with its suppressive effects on NFκB1 in the intestinal cells in the context of 
metabolic syndrome.  Further characterization of prebiotic functional fibers-associated 
epigenetic alterations may provide effective strategies to mitigate the low-grade 
inflammation in the context of intestinal as well as extra-intestinal diseases associated 
with dysbiosis. 
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3.7. Future Directions 1. To	include	more	of	epigenetic	marks,	including	both	repressive	and	expressive	marks,	on	more	pro-inflammatory	and	anti-inflammatory	mediators.	2. To	expand	this	colon	cancer	cell	model	into	other	disease	models	3. To	precisely	measure	the	metabolic	efficiency	of	mice	fed	with	RS4	so	that	we	could	explain	why	higher	feed	intake	of	RS4	did	not	result	in	to	high	weight	gain.	 	
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Figures and Legends 
 
Figure 3.1. Effects of NaBu on inflammatory gene expression in human intestinal 
epithelial cells  
(a) Concentration-dependent mRNA expression of inflammatory genes relative to a 
housekeeping gene, GAPDH.  Values are expressed as mean ± SEM (n = 6), ***p < 
0.001 compared with LPS treated (10 ng/ml) positive control. (b) Histone 3 lysine 27 tri-
methylation (H3K27me3) changes at promoter regions of inflammatory genes in cells 
treated with 1.25 mM NaBu for 5 h. Average percentage input ± SEM from each 
experiment (n ≥ 3) is plotted. *p < 0.05 compared with LPS treated positive control cells. 
Dr. Yi Liu helped with this figure.  
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Figure 3.2. Concentration-dependent effects of NaBu on NFκB1 in human intestinal 
epithelial cells.  
(a) Representative immunoblots showing the suppression of total cellular NFκB1 
subunits p105 and p50. Densitometric analyses showing relative protein expressions 
normalized to β-actin proteins and expressed as mean ± SEM (n = 3). *p < 0.05, 
compared with LPS (10 ng/mL) treated positive control. (b) Histone 3 lysine 27 tri-
methylation (H3K27me3) changes at promoter regions of NFκB1 in cells treated with 
different concentrations (0.31 to 1.25 mM) of NaBu for 5 h. Data points represent the 
input ± SEM (n ≥ 4). *p < 0.05, compared with LPS control. Dr. Yi Liu helped partly 
with this figure. 
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Figure 3.3. Effects of RS4 on feed intake and body weight in KK.Cg- Ay/a mice 
Cumulative food intake (a) and cumulative body weight gain (b) over a 12-week period 
in six-week old KK.Cg-Ay/a mice fed with 20% RS4 (resistant starch) or control diet. 
Data points represent the mean ± SEM (n = 3), *p < 0.05, **p < 0.01. Dr. Yi Liu helped 
with this figure. 
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Figure 3.4. Effects of RS4 on mice cecal weight, butyric acid levels and histone 
modification 
(a) Butyrate concentration (primary Y-axis on the left) per gram of cecal tissue 
(secondary Y-axis on the right) taken from KK.Cg-Ay/a mice after 12 week of feeding 
RS4 (20%) or control diet. Data represent the mean ± SEM (n = 3), *p < 0.05. (b) Diet-
induced differential tri-methylated histone 3 modifications on lysine 27 (H3K27me3) at 
promoter regions NFκB1 in the colon tissues of KK.Cg-Ay/a mice fed with either RS4 
(resistant starch, 20%) or control diet for 12 weeks. Average percentage input ± SEM 
from each experiment (n = 3) is plotted, **p < 0.01. Dr. Yi Liu helped partly with this 
figure. 
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Table 3.1. Primer sequences used for qRT PCR and ChIP assays 
Gene qRT PCR (SW480 cells) ChIP Assay (SW480 cells)/  
(Mice tissue) 
CCL2 F: 5’-agtctctgccgcccttct-3’ 
R: 5’-gtgactggggcattgattg-3’ 
F: 5’-gtggtcagtctgggcttaatg-3’ 
R: 5’-ctgctgagaccaaatgagca-3’ 
IL-10 F: 5’-cataaattagaggtctccaaaatcg-3’ 
R: 5’-aaggggctgggtcagctat-3’ 
F: 5’-aaggccaatttaatccaaggtt-3’ 
R: 5’-tttggtttcctcaccctactgt-3’ 
NFκB1 
 
 
 
GAPDH 
F: 5’-accctgaccttgcctatttg-3’ 
 
R: 5’-agctctttttcccgatctcc-3’ 
 
F: 5’-agccacatcgctcagacac-3’ 
R: 5’-gcccaatacgaccaaatcc-3’ 
F: 5’-ttggcaaaccccaaagag-3’/ 
F: 5’-cgatctgagtgtagccgaga-3’ 
R: 5’-ggtttcccacgatcgattt-3’/ 
R: 5’-gctgggcacaaaagtcaatc-3’ 
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Table 3.2. Composition of experimental diets per 100 grams 
Ingredients Control Diet RS4 Diet 
Midsol TM 501 31.77 27.07 
Fibersym RW2 0.00 23.5 
Powdered cellulose 18.80 0.00 
Casein – vitamin free 14.00 14.00 
Dextrin 13.67 13.67 
Sucrose 8.82 8.82 
Soybean oil 8.00 8.00 
AIN 93M mineral mix 3.50 3.50 
AIN 93M vitamin mix 1.00 1.00 
Choline Bitartrate 0.25 0.25 
L-Cystine 0.18 0.18 
t-Butylhyrdoquinone 0.0008 0.0008 
1 Midsol TM 50 is wheat starch with energy content 359.5 Kcal/100 g.  
2 Fibersym RW is resistant starch type 4 (85%, dry basis) with energy content 56.5 
Kcal/100 g 
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CHAPTER 4 . MATERNAL HIGH-FAT DIET AND GESTATIONAL DIABETES 
AFFECT HISTONE MODIFICATIONS ON CARDIO-METABOLIC GENE 
PROMOTERS IN OFFSPRING 
 
Related publication: Upadhyaya, B. et al. Maternal high-fat diet and gestational diabetes 
affect histone modifications on cardio-metabolic gene promoters in offspring (2016) [In 
preparation] 
 
4.1. Abstract 
A nutrient-mediated fetal metabolic programming in utero due to maternal high-
fat (HF) diet and gestational diabetes mellitus (GDM) increases the risk of the adult-onset 
of obesity, type 2 diabetes mellitus, and cardiovascular disease (CVD) in offspring. 
However, the precise mechanism of excess circulatory lipids in cardiac tissue-specific 
epigenetic programming remains poorly understood. In this pilot study, we seek to 
investigate a genome-wide chromatin landscape due to histone modifications (H3Ac, 
H3K4me3, and H3K27me3) in rat offspring heart tissue in response to either maternal HF 
(40% kcal) diet or streptozotocin-induced GDM, or both using a previously validated rat 
model. We observed that gestational diabetes was associated with cardiac hypertrophy 
(p<0.05). Chromatin immunoprecipitation sequencing of offspring’s heart tissue revealed 
the differential peaks distribution (FDR<0.1) due to Ac, H3K4me3 and H3K27me3 
histone modifications on the promoter regions mapped to rat genome. Downstream gene 
ontology analyses showed that out of 28 annotated genes, supposedly expressed 
(H3K4me3 gained peaks, FDR<0.1) in high fat-diet group, 15 genes were 1) annotated to 
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“metabolic process” in general and “positive regulation of cholesterol biosynthetic 
process” (FDR=0.0295) in particular; 2) overlapped with a total of 455 quantitative trait 
loci (QTL), primarily consisting of 66 QTL for blood pressure (19.34%), 24 QTL for 
body weight (5.27%), and 20 QTL for serum cholesterol (4.40%); 3) related to 
susceptibility or disease progression to several CVDs revealed through disease ontology 
analyses. Together, these findings show that maternal HF with or without GDM changes 
the cardiac epigenetic signature through histone modifications in rat offspring. This 
differential fuel-mediated epigenetic programming help assess the risks for obesity, 
diabetes, and CVDs beyond one generation, potentially leading to novel preventive and 
treatment strategies. 
Keywords: Cardiovascular disease, ChIP sequencing, developmental programing, 
gestational diabetes, histone modifications, maternal high-fat diet 
 
4.2. Introduction 
Gestational diabetes mellitus (GDM), one of the most common complications in 
pregnancy, occurs when hyperglycemia (> 92−125 mg/dL, fasting glucose) associated 
glucose intolerance is first diagnosed at any time of pregnancy, or in between 24 and 28 
weeks in particular [41]. 17.8% (9.3-25.5%) of overall pregnancies in the US are affected 
by GDM [42] and its occurrence parallels to the increasing obesity epidemics [39], which 
shows 34.4% of US women are obese in their child-bearing stage [40]. In addition to 
well-known risk factor of genetic susceptibility, over nutrition of the fetus in utero is 
another critical factor to shape the metabolic profile of offspring for the rest of their life 
[43, 44]. Siblings born to a diabetic mother possess a significantly higher risk of 
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developing diabetes later in life than in those born to the same mother before being 
diagnosed with diabetes [156]. Similarly, embryo transfer experiments in rats [157] 
further provided compelling evidence to support that adult metabolic consequences are 
caused by the diabetic environment in utero. 
The food plan that tightly controls the blood glucose level is often the first 
recommended strategy to manage GDM. However, the problems may arise when dietary 
carbohydrates go down (from ~60% to ~40%) and the compensatory fats usually go up 
(from ~20% to ~40%) [45] in order to meet the caloric needs of a rapidly growing fetus. 
Since heart constantly demands a high-energy source to maintain its contractile activity 
that requires a turnover of entire ATP pool in every 10 seconds, it has the ability to utilize 
all fuel sources including fatty acids, which indeed is the primary energy source for the 
normal adult heart [46]. Hence, the quantity as well as quality of the dietary fat during 
pregnancy plays a major role in cardiometabolic health outcomes in offspring above and 
beyond the pregnant mother [47]. Offspring of obese or diabetic mother have significant 
risk of cardiovascular diseases (CVD) at birth [158, 159] and throughout the life [160]. 
Interestingly, since studies show that many women even with good glycemic control have 
infants with CVD [159, 161], mechanistic research, which links adult nutrigenomic 
consequences to fuel-mediated fetal programming due to exposure of excess circulatory 
lipids in utero [162], are critically needed especially in combination with GDM.  
It has recently become apparent that posttranslational modification (PTM), which 
may be epigenetically inherited, are involved in gene expression or repression during 
developmental nutritional programing [163]. DNA methylation and histone modification, 
two major types of epigenetic marks that also crosstalk with each other, lead to a stable 
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long-term gene repression and a reversible short-term gene expression/repression, 
respectively [164]. These modifications alter gene expression by changing the 
conformation of the chromatin states into open or closed, hence modulating the 
accessibility of the promoter regions, upstream to the transcription start site, to bind with 
transcription factors and RNA Polymerase II before the gene transcription starts [165]. 
Only a few studies show maternal HF diet during pregnancy regulates rat offspring’s 
gene expression through histone modifications in liver-specific manner [166-168]. 
However, the genome-wide chromatin landscape in rat offspring heart tissue in response 
to maternal obesity and diabetes in pregnancy remains unknown.  
Since we already reported that a maternal HF diet further impairs cardiac 
functions due to lipid droplet accumulation, metabolic disturbances, oxidative stress, and 
mitochondrial dysfunction in rat offspring born to diabetic dams [169], this follow-up 
(proof-of-concept) study seek to investigate three most widely studied histone PTMs, 
namely acetylated histone 3 (H3Ac, a gene activation mark), trimethylated lysine at 
position 4 of histone 3 (H3K4me3, a gene activation mark), and trimethylated lysine at 
position 27 of histone (H3K27me3, a gene repression mark), following prenatal exposure 
to maternal HF diet and late gestation diabetes, either individually or in combination, 
using the previously validated rat model. 
 
4.3 Methods 
Animal study and dietary intervention  
Female Sprague-Dawley rats (Harlan Laboratories Inc., Indianapolis, IN) were 
fed either control diet (TD2018 Teklad, Harlan Laboratories, Madison, WI)) or high-fat 
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diet (TD95217 custom diet Teklad, Harlan Laboratories, Madison, WI) for at least 28 
days prior to breeding and throughout the pregnancy (Figure 4.1), following the 
guidelines of Institutional Animal Care and Use Committee at Sanford Research. All rats 
were housed in a temperature-controlled, light-dark cycled facility with water and chow 
supplied ad libitum. 18% and 40% of calories came from saturated and monounsaturated 
fat content in case of control diet (CD) and high-fat diet (HF), respectively, as we 
recently reported [169]. To induce gestational diabetes on day 14, pregnant dams were 
injected intraperitoneally either with 65mg/kg of streptozotocin (STZ, Sigma Life 
Sciences, St. Louis, MO) or 0.09 M citrate buffer (CB) as a placebo. Maternal late 
gestation blood glucose levels were monitored twice daily by tail nick sampling to a One 
Touch Ultra meter (LifeScan Inc., Milpitas, CA). The offspring were delivered normally 
on gestation day 22. Finally, neonate rat hearts from 4 different groups- CD with CB 
(CC), CD with STZ (CS), HF with CB (HC), and HF with STZ (HS)- were collected and 
snap-frozen after euthanizing the rat pups soon after the delivery.  
 
Chromatin immunoprecipitation (ChIP) assay  
Five to six frozen heart tissues were pooled to make >250mg/sample and 
homogenized followed by chromatin isolation using P-2001 ChromaFlashTM Chromatin 
Extraction Kit (Epigentek, Farmingdale, NY). Chromatin was sheared using 
Episonic2000 Sonication System (Epigentek, Farmingdale, NY) in 300 µl of ChIP buffer, 
followed by a quality control of sheared chromatin using fluorescence quantification. 4 µl 
of sheared chromatin was purified to obtain DNA, which was eluted with 20 µl of water. 
DNA fragment (100-300 bp) was quality-checked using Bioanalyzer analysis. For each 
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ChIP reaction, 10 µg of chromatin, 3 µg of H3K4me3 polyclonal antibody or 3 µg of 
H3K27me3 antibody or 3 µg of H3 Acetyl polyclonal antibody (all from Epigentek, 
Farmingdale, NY) and 6 µl of protein A/G beads were used. ChIPed DNA was eluted in 
20 µl of water. The H3K4me3, H3K27me3 and H3 Acetyl antibodies were tested and 
proven to be ChIP-grade.  
 
ChiP sequencing and analyses 
A ChIP-sequencing library was prepared using the EpiNext ChIP-Seq High 
Sensitivity Kit with amplification, DNA end polishing and adaptor ligation, following the 
manufacturer’s instruction. 10 nM of sample libraries were provided for next generation 
sequencing on a HiSeq 2500. The basic analysis of ChIP-Seq was based on the published 
protocol [170] utilizing Bowtie, version 1.0.0 [171] and MACS, version 2.1.0 [172]. Raw 
reads were quality checked using FastQC, version v0.10.1 [173] and mapped onto the rat 
RN5 genome sequence using Bowtie, version 1.0.0 [171].  The option of “-m 1” was 
activated so that only uniquely mapped reads were allowed to map. The mapping results 
in SAM were converted to BAM and sorted according to coordinates using samtools, 
version 0.1.19 [174]. Mapping results of each ChIP sample and the input sample were 
subjected to ChIP enriched peak calling. The option of “--broad” was activated to 
optimize the calling algorithm for broad binding regions. The called peaks are annotated 
to the nearest TSS (Transcript Starting Site) using ChIPpeakAnno, version 3.2.0 [175].  
ChIP quality control was performed using ChIPQC, version 1.2.2 [176]. All raw and 
processed sequencing data are deposited to NCBI GEO database under the accession 
number GSE84831. 
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Bioinformatics analyses  
Enriched peaks were called and then annotated to the nearest transcription start 
site of the genes. Peaks were visualized using Integrative Genomics Viewer (PMCID: 
PMC3346182). Genomic distribution of peaks were summarized in a heat map using 
Seqminer version 1.3.3 [177]. First, the genomic reference peak set 
(TSS.rat.Rnor_5.0.bed) was imported. Then the mapping results (BAM) were loaded; 
read densities were extracted and clustered (linear Kmeans clustering) using the default 
parameters. Differential binding analyses was carried out to determine the differential 
enrichment of cardiac-specific genes due to 4 different diet-conditions in all regions and 
in promoter region only. Promoter regions were further validated by having CpG islands 
using online database [178].  Likewise, a gene ontology analysis [179] was carried out to 
determine which biological processes that were triggered by 4 different diet-conditions. 
Enriched gene ontology analysis was carried out using online database GOEAST [180]. 
Rat genome database [181] was extensively used to annotate the gene, overlapping 
quantitative trait loci (QTL) and disease ontologies.  
 
Statistical analyses  
Statistical analyses were performed with Sigma Plot (Systat Software, Inc. San 
Jose, CA). To compare two diet-groups, a t-test was used. When the data were not normal, 
a Mann-Whitney U test was used. Principal coordinate analysis was used to show the 
difference among three histone modifications. The genome mapping statistics was 
extracted using Picard, version 1.90 [182]. Differential binding analyses was carried out 
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using a DiffBind Bioconductor R package [183].  Data were expressed as mean±SEM. A 
value of p<0.05 or FDR<0.1 was considered significant. 
 
4.4. Results 
Maternal late gestation STZ-induced diabetes increases the offspring’s heart weight 
To analyze the effects of maternal late gestational diabetes on the heart weight of 
the offspring, we compared the average weight of the hearts obtained from the pups 
whose mothers were fed either control diet (C) or high fat (H) diet with (CS and HS) or 
without (CC and HC) streptozotocin (S)-induced diabetes. Pups from CS group had 
significantly higher average heart weight compared to their control CC (55.64±1.95 mg 
vs. 48.94±2.03 mg, p=0.030). A similar effect of STZ was observed in high fat diet-fed 
mice groups combined with STZ (HS) when compared to diet-matched control group HC 
(52.92±1.62 mg vs. 44.91±2.30 mg, p=0.013) (Figure 4.2a).  In addition, pups from CS 
group had higher heart to body weight ratio when compared to control CC group 
(0.0089±0.0004 vs. 0.0071±0.0002, p=0.001). Although we observed the similar trend in 
HS vs. HC groups, the heart to body weight ratio were not significantly different 
(p=0.118). However, HS group had significantly higher heart to body weight ratio when 
compared to the CC control group (0.0082±0.0003 vs. 0.0071±0.0002, p=0.006) (Figure 
4.2b). Interestingly, these significantly higher heart weight in the offspring from the STZ 
groups corresponded to a trend of elevated maternal late gestation glucose levels induced 
by STZ when compared to CC and HC diet-matched control groups (305.30±92.01 
mg/dL vs. 82.23±3.92 mg/dL and 295.42±39.27 mg/dL vs. 88.30±2.61 mg/dL, 
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respectively) (Figure 4.2c). Taken together, gestational diabetes is related to enlargement 
of offspring’s heart, perhaps due to fuel mediated energy homeostasis. 
 
Differential histone modification profiles in cardiac tissue of offspring related to 
maternal HF diet and GDM in pregnancy 
Since we recently showed that the maternal high-fat diet alters the cardiac 
functions in offspring of diabetic pregnancies [169], we further seek to investigate the 
intergenerational effects of high-fat diet and gestational diabetes epigenetically through 
histone modifications. Using ChIP-grade antibodies, ChIP assays followed by ChIP 
sequencing revealed the differential peak distribution in offspring’s heart tissue due to Ac, 
H3K4me3 and H3K27me3 modifications, which were responsive to control or HF diet 
with or without STZ induction during pregnancies (Figure 4.3). A total of around 41000, 
73000 and 54000 significant peaks (FDR<0.1) were observed due to H3Ac, H3K27me3 
and H3K4me3 histone modifications, respectively, in control diet group. When we 
mapped peaks to the rat genome, only 29%, 11% and 36% of the total peaks overlapped 
to the known exonic regions (data not shown), which shows that most of H3K27me3 
peaks occurred in non-exonic and gene regulatory elements. These differential histone 
modification profiles were further validated with principal component analyses that 
showed 24% and 20% of variations were explained by principal component axes 1 and 2, 
respectively. Both being an expressive epigenetic mark, H3Ac and H3K4me3 
modifications clustered together, separated from a repressive epigenetic mark, 
H3K27me3 (Figure 4.4a). However, the effects of diet were not so distinct within each 
category of histone modification. Since we carried out ChIP sequencing from the 
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offspring’s’ heart whose mothers, not the offspring themselves, were fed a specific diet, 
we observed only subtle differences in the genome wide histone marks for H3Ac, 
H3K4me3, and H3K27me3 (Figure 4.4b). Interestingly, in 5kb upstream regions, 
combination of diabetes and high fat diet in gestation (HS group) showed relatively 
higher and lower mean densities (tag/50bp) than the individual ones (CS or HC alone) in 
case of expressive marks (H3Ac and H3K4me3) and repressive mark (H3K27me3), 
respectively (Figure 4.4c). Additionally, when we compared the different histone 
modifications from a representative high fat-diet group, H3K4me3 showed a much higher 
mean density that was slightly correlated (Pearson’s r=0.29) with another expressive 
H3Ac mark but without any correlation (Pearson’s r=0.09) with a repressive H3K27me3 
mark. Together, both the expressive histone marks, H3Ac and H3K4me3, functions 
similarly, which is different to that of H3K27me3. 
 
Diet-specific differential histone modifications in the gene promoter region 
In order to locate the histone modifications in the annotated genomic region, ± 
5kb distances to the nearest transcriptional start site (TSS) of genes annotated to rat 
genome 5.0 were identified and plotted. Around 40% of all the peaks were enriched in 
the upstream (- 5kb) of any known TSS, which was the consistent pattern for all four 
diet-groups.  In case of H3Ac modification, we observed a decrease in the total number 
of peaks in 5kb upstream of any known TSS in diabetes-induced (CS group) by 52% and 
in high fat diet-fed (HC group) by 53%. However, we found the opposite trend where CS 
and HC groups had additional 33% and 73% of K4me3 specific peaks and 56% and 70% 
of K27me3 specific peaks, respectively (Figure 4.5). Interestingly, K4me3 modification 
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also showed that the high-fat and diabetes combined (HS group) had an additional 89% 
of peaks when compared to the control (CC group), which is already 9.5% more than its 
diet-matched control (HC group) (Figure 4.5). In case of H3Ac, differential binding 
analyses (FDR< 0.1) revealed that CS and HC groups had two and three significantly lost 
peaks, respectively, in 5kb upstream gene promoter region when both were compared to 
CC group (Table 1). H3K27me3 showed a mixed response: six peaks were significantly 
gained for each CS and HC group, while three and one peaks were significantly lost for 
CS and HC groups, respectively (Table 4.1 and Table 4.2). However, two and 28 peaks 
were significantly gained in CS and HC groups, respectively, when compared to CC 
group in case of H3K4me3. Out of these 28 annotated genes supposedly expressed in 
high fat-diet group, 15 genes were related to “metabolic process” in the gene ontology 
category of biological process, validating the critical role of HF diet in GDM due to fetal 
metabolic programming in utero. 
 
Maternal high fat diet aggravates gestational diabetes that associates with metabolic 
consequences in the offspring 
Since both high fat diet and diabetes closely link to each other, we hypothesize a 
common gene network regulating metabolic process. As expected, H3K4me3 enriched 
two closely related genes, heat shock protein 1a1 (Hspa1a) and Hspa1b, were found to be 
associated with of CS diet (6.54 fold, FDR=0.02) and HC diet (5.62 fold, 
FDR<0.001)(Table 4.2). Remarkably, other maternal high-fat diet (HC group) induced 
offspring’s H3K4me3 enriched genes were ATP synthase mitochondrial Fo complex, 
subunit C3, subunit 9 (Atp5g3, 6.10 fold, FDR=0.07); Cytochrome P450, family 4, 
 87 
	
subfamily f, polypeptide 18 (Cyp4f18, 5.06 fold, FDR=0.01); autophagy associated 
transmembrane protein (EI24, 2.79 fold, FDR=0.02); endoplasmic reticulum 
oxidoreductase beta (Ero1lb, 6.66 fold, FDR=0.002); farnesyl diphosphate synthase 
(Fdps, 1.9 fold, FDR=0.06); hexose-6-phosphate dehydrogenase (H6pd, 6.75 fold, 
FDR<0.001); P450 (cytochrome) oxidoreductase (Por, 6.16 fold, FDR=0.06); solute 
carrier family 11, member 2 (Slc11a2, 6.7 fold, FDR<0.001) and tripartite motif 
containing 63, E3 ubiquitin protein ligase (Trim63, 4.99 fold, FDR<0.001). 
On the other hand, since H3K27me3 is a repressive mark, we considered the loss 
of peaks as a gain of gene function. We found several candidate genes on which 
H3K27me3 peaks were significantly lost in HF diet combined with GDM (HS group) 
when compared to GDM alone (CS group), suggesting the expression of those genes 
associated to further metabolic stress and diabetes. These candidate genes included ATP 
binding cassette subfamily B member 9 (Abcb9, 5.6 fold, FDR=0.02); Atp5g2 (5.92 fold, 
FDR=0.003); lysine demethylase 6B (Kdm6b, 5.37 fold, FDR=0.08); LIM domain 
binding 1 (Ldb1, 5.73 fold, FDR=0.01); nuclear receptor subfamily 4, group A, member 
3 (Nr4a3), 3.41 fold, FDR=0.004); RuvB-like AAA ATPase 2 (Ruvbl2, 3.40 fold, 
FDR=0.05); Solute carrier family 44, member 4 (Slc44a4, 6.17 fold, FDR<0.001); steroid 
sulfatase (microsomal), isozyme S (Sts, 1.82 fold, FDR=0.08); urocortin 2 (Ucn2, 2.61 
fold, FDR=0.06). Similarly, a significant gain of H3K27me3 peaks in two candidate 
genes were supposed to be repressed in HS group when compared to CS group. These 
candidate genes were adenylate kinase 3 (Ak3, 1.95 fold, FDR=0.09) and signal 
transducer and activator of transcription 5B (Stat5b, 3.76 fold, FDR=0.09). Taken 
together, maternal high fat diet not only shares with gestational diabetes some candidate 
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genes that affect the metabolic consequences in the offspring but also aggravates the 
gestational diabetes. 
 
Maternal high fat diet and gestational diabetes affect the genes and QTLs related to 
metabolic diseases in the offspring 
Some of the gene ontologies related to mitochondrial function were enriched 
among those 15 genes of interest in case of H3K4me3 due to high fat diet. Interestingly, 
both diabetic diet (CS) and high-fat diet (HC) groups showed H3K4me3 peaks gain in 
heat shock protein 1a and 1b in common. Enriched gene ontology analyses revealed that 
both Hspa1a and Hspa1b were enriched for “primary metabolic process” in HF-induced 
H3K4me3 modification (log2 odd ratio 1. 38, FDR=0.06) (Table 3).  Moreover, enriched 
gene ontology of “positive regulation of cholesterol biosynthetic process” (FDR=0.0295) 
was associated to farnesyl diphospho synthase (Fdps) and P450 (cytochrome) 
oxidoreductase (Por) (Table 4.3 and Supplementary Table 4.1). Despite the genes of 
interest belong to different chromosomes or genomic regions, we found that those 15 
genes overlap with a total of 455 QTLs, primarily consisting of 66 QTLs for blood 
pressure (19.34%), 24 QTLs for body weight (5.27%), and 20 QTLs for serum 
cholesterol (4.40%)(Table 4). Particularly, Fdps overlapped with a total of 33 QTLs, out 
of which 22 QTLs (66.67%) were related to blood pressure. Atp5g3 overlapped with a 
total of 22 QTLs, out of which 9 QTLs (40.91%) were related to body weight. Similarly, 
Por and Ero1lb overlapped with a total of 12 and 19 QTLs, respectively, out of which 2 
(16.67%) and 3 (15.79%) QTLs, respectively, were related to serum cholesterol (Table 
4.4, suggesting the putative role of HF diet in hypercholesterolemia. Furthermore, disease 
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ontology revealed that Hspa1a gene was related to the disease progression of systolic 
heart failure and other cardiovascular diseases like coronary disease, atherosclerosis, and 
acute coronary syndrome.  Hspa1b, a close relative of Hspa1a, was related to obesity, 
type 2 diabetes mellitus, and hyperlipidemia. H6PD was related to experimental diabetes 
mellitus and inborn errors on metabolism, further supporting the role of HF diet either 
alone or in combination with GDM on the fetal metabolic programming of adult-onset 
diabetes and cardiovascular diseases.  
 
4.5. Discussion 
A successful pregnancy should primarily be defined not only by the outcome at 
birth but also by the health status in later life [44]. A growing number of animal models 
and human epidemiological studies have shown that fetal metabolic programming play a 
crucial role in perpetuating the vicious cycle of cardiometabolic conditions through one 
generation to the other [184] but the molecular mechanisms remain poorly understood. 
To this context, we previously reported that maternal HF diet (40% kcal from fat) 
aggravates the gestational diabetes through lipid droplet accumulation, metabolic 
abnormalities, oxidative stress, and mitochondrial dysfunction in a rat model [169]. To 
our knowledge, this follow-up study is the first to further explain the heart tissue-specific 
epigenetic marks in the rat offspring born to diabetic and obese pregnancy, utilizing a 
genome-wide ChIP sequencing.  
Using a rat model of gestational diabetes with or without maternal obesity [169], 
we introduced STZ-induced diabetes in pregnant rats at gestational day 14 (Figure 4.1), 
simulating GDM in humans that occurs in third-trimester of pregnancy [41].  This is 
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appropriate because the late GDM is less likely associated with congenital heart, which 
mostly occurs in early pregnancy [185, 186], minimizing the confounding cardiovascular 
outcomes due to maternal diet. HF diet, the second half of the intervention in this study, 
included more saturated (~13% kcal from fat) and monounsaturated (~17% kcal from fat) 
fatty acids but with similar polyunsaturated fatty acids (~8% kcal from fat) when 
compared to CD diet, showing a translational or feasible diet choice for typical 
Americans [187]. More recently paternal diet has also been shown to play a key role in 
the metabolic programming of the offspring [188]. In our study, female rats were bred 
with normal control diet-fed males, ruling out the possible effects of the paternal diet on 
the observed outcomes. 
The fuel-mediated teratogenesis hypothesis shows the association between 
maternal hyperglycemia in pregnancy and obesity or cardiovascular complications in 
fetus [156]. In our study, late gestational maternal glucose was elevated, as expected, 
after STZ-induced diabetes (Figure 4.2c). However, the concomitant high level of 
maternal insulin that we previously observed [169] cannot freely cross the placenta to the 
fetus [189]. Therefore, in order to respond to this high glucose load the developing fetal 
pancreas produces additional insulin, causing fetal hyperinsulinemia as we and others 
previously reported [169, 190]. Interestingly, insulin resistance, a biomarker of type 2 
diabetes, has also been associated with altered cardiac singling and the development of 
hypertension-associated left ventricular hypertrophy [190, 191]. This aligns with our 
observation that weight of the offspring hearts (Fig 2a) and heart to body ratio (Figure 
4.2b) were significantly higher in STZ-induced diabetic group (CS) when compared to 
control group (CC).  
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Since histone modification, mostly of short-term and reversible in nature, usually 
precedes the DNA methylation that facilitates a long-term gene repression [164], here in 
this proof-of-concept study we focused only few well-studied representative histone 
marks: H3Ac, H3K4me3, and H3K27me3 using a validated ChIP-grade antibodies. 
These choices were based on the proposal that developmental specification is 
accompanied by a striking transition form a permissive chromatin state with widespread 
remodeling to a restrictive state with pervasive Polycomb repression [192]. Broadly, the 
oxidative stress-mediated regulation cascade is the common mechanistic link among the 
pathogenesis of diabetes, hypertension, and other related inflammatory diseases [193]. In 
our study, several H3K4me3 peaks, which are the gene activating marks, were 
differentially gained in the promoter regions of genes pertaining to metabolic stress 
regulation, including Atp5g3 associated with mitochondrial injury [194], Ei24 reported to 
have an effect on autophagy [195], H6pd associated with fuel metabolism and 
experimental diabetes mellitus [196], Erol1b associated with decrease insulin synthesis 
leading to diabetes mellitus [197], SLC11A2 increased with body fatness [198], CYP4F 
associated with oxidation of inflammatory lipid substrates [199], and Trim63 associated 
with several human heart conditions, such as hypertrophic cardiomyopathy and chronic 
heart failure [200].  
Notably, Hspa1a and Hspa1b were the common candidate genes in HF and CS 
treated groups, showing a degree of common pathways of obesity and diabetes. Indeed, 
increased Hspa1a is not only linked with HF-associated oxidative stress in metabolic 
syndrome patients [201] but also correlates with HbA1c values in women with GDM 
[202]. This could be the reason why our disease ontology analyses linked Hsp1a1 and 
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Hspa1b with severe disease progression to systolic heart failure [203] and CVD [204]. 
Furthermore, Por and Fdps showed enriched “metabolic process” gene ontology in 
general and “positive regulation of cholesterol biosynthesis process” in particular (Table 
3). Por is associated with microsomal P450s-mediated xenobiotic metabolism as well as 
cholesterol and bile acid synthesis [205], while Fdps is associated with cholesterol 
biosynthesis and hypercholesterolemia [206]. Interestingly, all of these annotated genes 
overlapped with “blood pressure” QTLs while most of them overlapped with “cholesterol 
synthesis” QTLs, which clearly demonstrates that the epigenetic cues already in place at 
birth affect the adult-onset diseases like atherosclerosis, hypertension, and CVD.  These 
results further corroborate our previous findings that HF diet in GDM causes oxidative 
stress and mitochondrial dysfunction [169]. 
Since H3k4me3 (active) and H3K27me3 (inactive) modifications co-exist to form 
bivalent promoters in early life, promoters quickly respond to the developmental stimuli 
and change their histone modification state mainly through H3K27me3 demethylation 
[207]. Interestingly, when we compared the effects of HF diet on diabetic background 
(HS vs. CS groups), a lysine demethylase enzyme, Kdm6b, was associated with a 
significant H3K27me3 loss [208]. This suggests that several candidate genes with 
H3K27Me3, including Kdm6b, were likely upregulated when HF diet is provided in 
GDM. To this context, our candidate genes, ABCB9 (associated with type 2 diabetes 
[209]; ATP5G2 (associated with insulin secretion [210]; Ldb1 [211], NR4A3 [212] and 
SLC44A4 [213](all associated with β-cell and pancreatic islets functions); RUVBL2 
(associated with insulin-stimulated GLUT4 translocation [214]; Sts (associated with HF 
diet and ob/ob models of obesity and type 2 diabetes [215]; and Ucn2 (associated with 
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heart failure patients [216], lost a repressive H3K27me3 mark and were likely expressed. 
Interestingly, in case of H3K27me3 peaks gain in the promoter regions of AK3 
(associated with downregulation of insulin secretion [217]) and STAT5B (associated with 
negative regulation in adipogenesis [218] further validated the HF-induced gene 
repression of AK3 and STAT5B, leading to more insulin secretion and adipogenesis. 
Hence, epigenetic processes represent a central underlying mechanism of 
developmental programming of T2D and CVD [219]. In a similar study to ours, rat adult 
offspring, exposed to a maternal HF diet in utero, at 6 months of age showed 
significantly higher body weights, greater adiposity, and increased triacylglycerol levels 
than that of control rats in spite of their similar weights at birth [220]. To this context, we 
also expect that it might take a longer time to manifest more phenotypic outcomes 
because there were no significant differences in the birth weights observed among 
offspring in different groups (data not shown). Indeed, we have already collected heart 
tissues of the weaned pups (3 weeks age) and adult rats (12 weeks age) from the same 
breeding mates kept in the same diet groups. Due to limited resources, only the neonatal 
hearts were analyzed for ChIP sequencing to report in this pilot study. Our prospective 
and comprehensive longitudinal study will also encompass whether the effects of post-
natal dietary habits at different life stage of the offspring can alter the epigenetic 
landscape set at the birth, making them either less or more prone to adult-onset CVD. 
Since the fetal primordial germ cells, that determines the fate of F2 generation is also 
likely affected by intrauterine environment [219], studies highlighting the importance of 
HF diet and GDM in the context of intergenerational and transgenerational (F3 
generation and beyond) metabolic programming [221] above and beyond the first 
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generation is imperative. Moreover, considering the gender-specific fetal response to the 
same environmental insults due to maternal as well as paternal diet would reveal more 
information on differential metabolic profiles due to sexual dimorphism and genomic 
imprinting. Besides, the functional microarray or RNA Seq would allow us to delineate 
the functionality of epigenetic marks annotated to the nearest transcription start sites. 
Therefore, characterizing these altered epigenetic marks at-birth by taking the surrogate 
tissues like placenta and cord blood with a minimal invasive technique could function as 
the first-step in developing a clinical biomarker based on the intra-uterine environment, 
which merits further study on screening the fetus at an increased risk of adult-onset 
chronic diseases. 
 
4.6. Conclusion 
This follow-up study of fuel-mediated cardiac dysfunction in offspring [169] is 
the first to further explain the role of maternal HF diet on heart tissue-specific differential 
histone modifications (H3Ac, H3K4me3, H3K27me3) in the rat offspring born to obese 
and/or diabetic pregnancy, utilizing a genome-wide ChIP sequencing and bioinformatics 
analyses. Identification of this reversible epigenetic landscape in utero and its association 
to risks for adult-onset of chronic CVDs provides an effective strategy for novel cardio-
metabolic health management in next generation and future generation 
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4.7. Future Directions 
1. To carry out ChIP sequencing and RNA sequencing on the same tissue so that the 
histone modifications and putative functionality can be compared at the same 
time. 
2. To carry out ChIP sequencing of heart tissues collected from different age groups 
(e.g., 3 weeks or 12 weeks in rats) so that the changing epigenetic landscape can 
be monitored. 3. To carry out transgenerational metabolic programming study that involves 
feeding of mother or father or both and observing the epigenetic effects in 3 or 
more generations to come.	 	
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Figures and Legends 
 
Figure 4.1: Study timeline  
Female Sprague-Dawley rats were randomized into four groups and fed high fat diet (HF) 
or control diet (CD) for 28 days prior to their breeding and throughout the pregnancy. On 
gestational day 14, each HF or CD group was treated with intraperitoneal injection of 
Streptozocin (STZ, 65 mg/Kg) or citrate buffer (CB) as a control. Pups were normally 
delivered on gestational day 21 and sacrificed for their hearts collection. One of our 
collaborators, Dr. Michelle Baack developed and carried out the rat model used in this 
study. 
 
 
 
Figure 4.2: Physiological characteristics pups and their dams under study 
Bar graphs showing the higher neonatal heart weight (a) and neonatal heart to body 
weight ratio (b) that corresponds to elevated maternal late gestation glucose levels (c) in 
Streptozotocin-induced diabetes groups. n= 10-12 (a and b), n= 2 (c). *p<0.05, **p<0.01, 
***p<0.001 (t-test). CC, controls; CS, diabetes induced; HC, high-fat diet fed; HS, high-
fat fed and diabetes induced. One of our collaborators, Dr. Michelle Baack analyzed the 
characteristics of dams and pups under study. 
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Figure 4.3: Peaks detection in ChIP sequencing  
Representative genomic region of a negative strand (chromosome 7) near the 
transcriptional start site of Atp5g2 gene, illustrating 5kb upstream peaks in cyan 
(acetalyation), red (H3K427me3), blue (H3K4me3), and grey (Input control) colors. CC, 
controls; CS, diabetes induced; HC, high-fat diet fed; HS, high-fat fed and diabetes 
induced. 
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Figure 4.4: Differential histone modification profiles 
a) Principal component analyses showing different profiles among three histone 
modifications. Axes 1 and 2 possess 24 and 20% of variations, respectively. b) Genome 
wide differential histone marks in H3Ac, H3K4me3 and H3K27me3 modifications due to 
different diets. Read density in +/- 5 kb of any known transcriptional start site for each 
marker are clustered and visualized in a heat map, each of which consists of four panels 
in the order of CC (control), CS (diabetes-induced), HC (high fat diet-fed), and HS 
(combined HC and CS) from left to right. From the vertical view, clusters with the central 
density profile are located at the top, followed by clusters with peaks in the -5 kb region 
(marked under the black lines), those with peaks in the +5 kb region, those with diffuse 
read density, and those without significant read density. c) Corresponding mean density 
(tag/50bp) plots for H3Ac, H3K4me3 and H3K27me3 modifications in +/- 5 kb of any 
known transcriptional start site due to different diets. 
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Figure 4.5. Peaks overlapping any 5kb upstream region of known exons  
For each histone modifications of H3Ac (Ac), H3K4me3 (K4) and H3K27me3 (K27), 
peaks with 5kb upstream of any known TSS are counted and plotted as indicated. CC, 
controls; CS, diabetes induced; HC, high-fat diet fed; HS, high-fat fed and diabetes 
induced 
  
 101 
	
Table 4.1. Diet-specific differential binding of peaks in respective histone 
modification in genomic and 5kb upstream region 
Histone 
Modification 
CC vs CS  
(gained/lost peaks) 
CC vs HC 
(gained/lost peaks) 
CS vs HS 
(gained/lost peaks) 
All 
region 
Promoter 
Region 
All 
region 
Promoter 
Region 
All 
region 
Promoter 
Region 
H3Ac 0/32 0/2 5/103 0/3 0/0 0/0 
H3K4me3 8/6 2/0 449/11 28/0 1/6 1/0 
H3K27me3 186/82 6/3 309/114 6/1 403/226 4/22 
CC, controls; CS, diabetes induced; HC, high-fat diet fed; HS, high-fat fed and diabetes 
induced 
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Table 4.2. List of “metabolic process” candidate genes with differentially bound 
peaks 
Modificati
on Diets Genes Ensemble ID Fold FDR 
H3Ac CC vs CS Myrf ENSRNOG00000028274 -5.53 1.59E-02 
H3K4me3 CC vs CS Hspa1a ENSRNOG00000050647 6.54 2.49E-02 
  
Hspa1b ENSRNOG00000050647 6.54 2.49E-02 
 
CC vs HC Atp5g3 ENSRNOG00000001596 6.10 7.63E-02 
  
Cyp4f18 ENSRNOG00000015751 5.06 1.27E-02 
  
Ei24 ENSRNOG00000030391 2.79 2.42E-02 
  
Ero1lb ENSRNOG00000002609 6.66 1.96E-03 
  
Fdps ENSRNOG00000043377 1.92 5.66E-02 
  
H6pd ENSRNOG00000017523 6.75 7.39E-04 
  
Hspa1a ENSRNOG00000050647 5.62 3.76E-05 
  
Hspa1b ENSRNOG00000050647 5.62 3.76E-05 
  
Mapk8ip2 ENSRNOG00000032828 6.16 6.08E-02 
  
Napsa ENSRNOG00000019854 6.18 5.66E-02 
  
Nfix ENSRNOG00000002983 2.09 8.40E-02 
  
Por ENSRNOG00000001442 6.16 6.08E-02 
  
Slc11a2 ENSRNOG00000019550 6.73 9.55E-04 
  
Trim63 ENSRNOG00000016543 5.00 9.51E-04 
  
Zim1 ENSRNOG00000015071 6.28 3.43E-02 
H3K27me3 CC vs CS Bmp8b ENSRNOG00000033209 2.25 3.03E-02 
  
Gli1 ENSRNOG00000025120 2.77 6.51E-02 
  
Rps29 ENSRNOG00000032542 3.73 7.29E-02 
  
Snapc3 ENSRNOG00000010825 4.51 7.29E-02 
  
Ccdc126 ENSRNOG00000009322 -4.10 9.17E-02 
 
CC vs HC Dstyk ENSRNOG00000021298 2.57 8.56E-02 
  
Lhpp ENSRNOG00000017097 5.63 1.69E-02 
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Zfp444 ENSRNOG00000015517 -5.83 4.77E-02 
 
 
CS vs HS 
Ak3 ENSRNOG00000015273 1.95 9.12E-02 
  
Stat5b ENSRNOG00000019075 3.76 8.66E-02 
  
Abcb9 ENSRNOG00000001082 -5.60 2.22E-02 
  
Atp5g2 ENSRNOG00000015320 -5.92 3.41E-03 
  
B3gnt3 ENSRNOG00000018764 -5.79 7.71E-03 
  
Kdm6b ENSRNOG00000037613 -5.37 7.80E-02 
  
Ldb1 ENSRNOG00000018468 -5.73 1.10E-02 
  
Metap1 ENSRNOG00000012947 -5.58 2.46E-02 
  
Nfic ENSRNOG00000004505 -4.58 3.65E-03 
  
Nr4a3 ENSRNOG00000005964 -3.41 3.70E-03 
  
Ruvbl2 ENSRNOG00000020793 -3.40 5.43E-02 
  
Slc44a4 ENSRNOG00000000878 -6.18 2.79E-04 
  
Snapc3 ENSRNOG00000010825 -4.17 4.90E-02 
  
Sts ENSRNOG00000032487 -1.82 7.95E-02 
  
Ucn2 ENSRNOG00000020655 -2.61 5.70E-02 
  
Uqcrq ENSRNOG00000048174 -5.73 1.10E-02 
CC, controls; CS, diabetes induced; HC, high-fat diet fed; HS, high-fat fed and diabetes 
induced   
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Table 4.3. List of “metabolic process” candidate genes (high fat diet) with gene 
ontology enrichment  
Gene Enriched GO 
ID 
Description of GO Log2 
Odd 
Ratio 
FDR 
Atp5g3 GO:1901360 Organic cyclic compound metabolic process 1.96 0.0976 
 GO:0044238 Primary metabolic process 1.38 0.0636 
Cyp4f18 GO:1901360 Organic cyclic compound metabolic process 1.96 0.0976 
 GO:0044248 Cellular catabolic process 2.87 0.0976 
 GO:0044238 Primary metabolic process 1.38 0.0636 
 GO:0016709 Oxidoreductase activity 6.13 0.0976 
Ei24 GO:0030308 Negative regulation of cell growth 4.80 0.0726 
Fdps GO:0045542 Positive regulation of cholesterol biosynthetic 
process 
8.68 0.0195 
 GO:1901360 Organic cyclic compound metabolic process 1.96 0.0976 
 GO:0044238 Primary metabolic process 1.38 0.0636 
H6pd GO:1901360 Organic cyclic compound metabolic process 1.96 0.0976 
 GO:0044238 Primary metabolic process 1.38 0.0636 
Hspa1a GO:0008180 COP9 signalosome 6.31 0.0976 
 GO:1901360 Organic cyclic compound metabolic process 1.96 0.0976 
 GO:0044248 Cellular catabolic process 2.87 0.0976 
 GO:0090083 Regulation of inclusion body assembly 8.09 0.0312 
 GO:0044238 Primary metabolic process 1.38 0.0636 
Hspa1b GO:0008180 COP9 signalosome 6.31 0.0976 
 GO:0043281 Regulation of cysteine-type endopeptidase 
activity involved in apoptotic process 
4.43 0.0976 
 GO:1901360 Organic cyclic compound metabolic process 1.96 0.0976 
 GO:0044248 Cellular catabolic process 2.87 0.0976 
 GO:0090083 Regulation of inclusion body assembly 8.09 0.0312 
 GO:0044238 Primary metabolic process 1.38 0.0636 
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Mapk8ip2 GO:0044238 Primary metabolic process 1.38 0.0636 
Napsa GO:0044238 Primary metabolic process 1.38 0.0636 
Nfix GO:1901360 Organic cyclic compound metabolic process 1.96 0.0976 
 GO:0044238 Primary metabolic process 1.38 0.0636 
Por GO:0045542 Positive regulation of cholesterol biosynthetic 
process 
8.68 0.0195 
 GO:0043281 Regulation of cysteine-type endopeptidase 
activity involved in apoptotic process 
4.43 0.0976 
 GO:0044248 Cellular catabolic process 2.87 0.0976 
 GO:0044238 Primary metabolic process 1.38 0.0636 
 GO:0016709 Oxidoreductase activity 6.13 0.0976 
Slc11a2 GO:0043281 Regulation of cysteine-type endopeptidase 
activity involved in apoptotic process 
4.43 0.0976 
 GO:1901360 Organic cyclic compound metabolic process 1.96 0.0976 
 GO:0044238 Primary metabolic process 1.38 0.0636 
Trim63 GO:0044248 Cellular catabolic process 2.87 0.0976 
 GO:0044238 Primary metabolic process 1.38 0.0636 
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Table 4.4. Metabolic process candidate QTLs obtained from the candidate genes 
(high fat diet specific) 
 QTL Count (Percent Total) 
Blood 
Pressure 
Body 
Weight 
Glucose 
Level 
Insulin 
Level 
Insulin 
Dependent 
Diabetes 
Mellitus 
Non-insulin 
Dependent 
Diabetes 
Mellitus 
Serum 
Cholesterol 
Gene QTL 
Total 
        
 455 88 
(19.34%) 
24 
(5.27%) 
7 
(1.54%) 
5 
(1.10%) 
4 
(0.88%) 
15 
(3.30%) 
20 
(4.40%) 
Atp5g3 22 7 
(31.82%) 
9 
(40.91%) 
1 
(4.55%) 
   1 
(4.55%) 
Cyp4f18 14 3 
(21.43% 
3 
(21.43%) 
 2 
(14.29%) 
 1 
(7.14%) 
1 
(7.14%) 
Ei24 19 7 
(36.84%) 
 2 
(10.53%) 
1 
(5.26%) 
 2 
(10.53%) 
2 
(10.53%) 
Ero1lb 19 7 
(36.84%) 
1 
(5.26%) 
2 
(10.53%) 
1 
(5.26%) 
 2 
(10.53%) 
3 
(15.79%) 
Fdps 33 22 
(66.67%) 
3 
(9.09%) 
   2 
(6.06%) 
 
H6pd 12 7 
(58.33%) 
     2 
(16.67%) 
Hspa1a 3 1 
(33.33%) 
1 
(33.33%) 
  1 
(33.33%) 
  
Hspa1b 3 1 
(33.33%) 
1 
(33.33%) 
  1 
(33.33%) 
  
Mapk8ip2 12 6 
(50.00%) 
   1 
(8.33%) 
2 
(16.67%) 
1 
(8.33%) 
Napsa 16 7 
(43.75%) 
1 
(6.25%) 
1 
(6.25%) 
  2 
(12.50%) 
2 
(12.50%) 
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Nfix 4 1 
(25.00%) 
     1 
(25.00%) 
Por 12 6 
(50.00%) 
 1 
(8.33%) 
1 
(8.33%) 
1 
(8.33%) 
1 
(8.33%) 
2 
(16.67%) 
Slc11a2 8 5 
(62.50%) 
    1 
(12.50%) 
 
Trim63 19 7 
(36.84%) 
3 
(15.79%) 
   1 
(5.26%) 
4 
(21.05%) 
Zim1 6 1 
(16.67%) 
2 
(33.33%) 
   1 
(16.67%) 
1 
(16.67%) 
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CHAPTER 5 . PHENETHYL ISOTHIOCYANATE INHIBITS ALDEHYDE 
DEHYDROGENASE ACTIVITY AND TARGETS REACTIVE OXYGEN 
SPECIES-MEDIATED APOPTOSIS IN HUMAN CANCER STEM CELLS 
 
Related publications:  
Wang, D., Upadhyaya, B. et al. Phenethyl isothiocyanate upregulates death 
receptors 4 and 5 and inhibits proliferation in human cancer stem-like cells BMC Cancer 
2014 14:591[Equal first author] 
Upadhyaya, B. et al. Phenethyl isothiocyanate inhibits aldehyde dehydrogenase 
activity and targets reactive oxygen species-mediated apoptosis in human cancer stem 
cells (2016) [In preparation]. 
 
5.1. Abstract  
Aldehyde dehydrogenase family 1 (ALDH1) is a cancer stem cell (CSC) marker 
that associates with tumor malignancy and self-renewal properties of stem cells in 
different tumors. Tumor cells also have higher load of oxidative stress than normal cells 
where as cancer stem cells (CSCs) are more stable because of the redox balance 
machinery. Mounting evidence has supported that further exposure of reactive oxygen 
species (ROS)-load will exhaust their antioxidant potential and induce even more 
apoptosis in CSCs compared to cancer cells. However, how phenethyl isothiocyanate 
(PEITC), a prooxidant and an inhibitor of liver ALDH2, selectively targets cervical CSCs 
has remained unknown. Hence, we seek to investigate whether PEITC could inhibit 
ALDH1 and cell proliferation and induce ROS in HeLa CSCs (hCSCs). Results showed 
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that sphere-culture method significantly enriched CSCs from HeLa cells (p<0.05). Flow 
cytometry revealed that PEITC attenuated ALDHhi cells in hCSCs (p<0.05). ROS assay 
showed that PEITC induced oxidative stress in hCSCs, which was glutathione dependent. 
PEITC also inhibited a transcription factor Sp1 and multidrug resistance protein, P-
glycoprotein in hCSCs (p<0.05). Xenotransplantation study in a non-obese diabetic, 
severe combined immunodeficient (NOD/SCID) mouse model and histopathology 
showed anti-tumorogenic and anti-metastatic potential of PEITC in vivo. Taken together, 
this proof-of-concept study showed that PEITC effectively targets multi-drug resistant 
and metastatic hCSCs through inhibition of ALDH enzyme and Sp1 transcription factor 
and induction of oxidative stress and apoptosis in cervical hCSCs. Therefore, PEITC 
commonly found in cruciferous vegetables may offer a novel approach to target CSCs for 
improving therapeutic outcomes in cancer patients. 
Key words: ALDH, cancer stem cells, oxidative stress, phenethyl isothiocyanate, 
Sp1 protein  
 
5.2. Introduction  
Cancer stem cells (CSCs), a subset of cancer cells (0.1- 30%) with self-renewal 
and differentiation potential, have been implicated in tumor initiation, maintenance, 
metastasis, and recurrence of a number of cancer types [50, 51]. Survival of CSCs from 
chemo or radiotherapy include expression of drug efflux transporters, expression of anti-
apoptotic proteins, enhanced activity of repair enzyme, hypoxic stability, vascular niche, 
and dormancy [51]. To identify and isolate CSCs from within a heterogeneous population 
of cancer cells, several CSC putative surface markers have been proposed, such as 
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CD133+, CD24- and CD44+, that often associate with aggressive cancer types and poor 
prognosis [222, 223]. Recent studies have also shown that aldehyde dehydrogenase 
family 1 (ALDH1) is a CSC marker that associates with tumor malignancy and self-
renewal properties of stem cells in different tumors, including breast [52], head and neck 
[224], melanoma [225], hepatic [226], pancreatic [227], colon [53], lung [228], prostrate 
[229], bladder [230] ovarian [231], endometrial [232] and cervical [54, 55] cancers.  
Hence, CSCs-targeted therapy is of growing interest and concern given the fact 
that conventional chemo or radiotherapy cannot and does not eradicate the drug-resistant 
CSCs [51]. This is due to the activity of drug efflux transporter proteins or ATP binding 
cassette (ABC) transporters, such as P-glycoprotein (P-gp), breast cancer resistance 
protein (BCRP) and multidrug resistance-associated proteins (MRP), which usually 
overexpress in drug-resistant CSCs [233]. Particularly, P-gp having a broad substrate 
specificity is considered as a main impeding factor in the anticancer therapy [234]. Since 
P-gp protein is mediated through expression of MDR1 gene, activation of MDR1 
promoter region gets activated with specificity protein (Sp1) [235]. Sp1 being a 
ubiquitous transcription factor for Sp1-regulated genes involved in cell proliferation and 
cancer development [236], there is a need of anti-cancer compound that does not easily 
get excreted out of the cell and target Sp proteins in CSCs. 
Besides drug-resistance potential, CSCs possess another survival machinery of 
enhanced redox homeostasis. Due to increased oxidative metabolism and shortage of 
nutrient supply rapidly growing cancer cells have higher levels of reactive oxygen species 
(ROS) than normal healthy cells [237]. Hence, one established strategy to induce 
apoptosis and kill only cancer cells is to further increase the ROS levels, since the 
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threshold to resist elevated ROS levels is usually low in cancer cells when compared to 
normal cells. However, the challenges arise due to the fact that the CSCs possess lower 
redox stress due to high levels of anti-oxidant machineries [238], such as glutathione 
(GSH) and lipid peroxidation enzyme, aldehyde dehydrogenase (ALDH). ALDH 
enzymes irreversibly catalyze the oxidation of aldehydes to their respective carboxylic 
acids, thereby reducing the cellular oxidative stress [239]. Therefore, to exploit the 
similar effect of elevated ROS in CSCs, naturally occurring pro-oxidant dietary 
compounds is essential because of their no side effects even in the high doses. 
Phenethyl isothiocyanate (PEITC) is a biologically active dietary compound present in 
cruciferous vegetables, including watercress, broccoli, cabbage, and cauliflower [56, 
240]. Others and we have previously reported the anti-inflammatory [57, 58] and chemo-
preventive characteristics of PEITC against various cancers [59, 61, 240]. Because of its 
non-toxicity [63] and high efficacy among other isothiocyanates (ITCs) [241] PEITC is 
currently under phase II clinical trials for lung cancer (NCT00691132). PEITC depletes 
GSH and selectively inhibits proliferation of cancer cells due to elevated ROS-
accumulation inside the cells [242, 243]. Interestingly, PEITC also inhibits liver ALDH 
enzyme in the context of ethanol administration in rats [244]. However, the pro-oxidant 
effect of PEITC in inhibiting ALDH1 in the context of CSCs and more specifically 
cervical CSCs is entirely unknown. 
Apoptosis, or programmed cell-death, is essential to maintaining tissue 
homeostasis, and its impairment is implicated in many human diseases, including cancers 
[245]. Since we recently showed that PEITC targets CSCs through apoptosis [61], in this 
study we hypothesized that PEITC induces ROS-mediated apoptosis in CSCs and inhibits 
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a CSC marker ALDH1 and drug efflux transporter protein P-gp, using a cervical cancer 
HeLa sphere culture model in vitro and non-obese diabetic/ severe combined immune 
deficit (NOD/SCID) mouse model in vivo. 
 
5.3. Materials and Methods 
Sphere cultures of hCSCs 
Following our previous work [61], human cervical HeLa cell line (CCL-2, 
American Type Culture Collection, Manassas, VA) was cultured and maintained in a T-
25 flask with Dulbecco’s modified eagle’s medium (DMEM) containing 4 mM L-
glutamine and 4.5 g/L glucose (HyClone, Logan, UT), supplemented with 10% heat-
inactivated fetal bovine serum (Invitrogen, Grand Island, NY) and 1% penicillin (25 
U/ml)/streptomycin (25 µg/ml) (Sigma-Aldrich, St. Louis, MO) in a 5% CO2-humidified 
atmosphere at 37°C. HeLa cells were trypsinized with TrypLE (Invitrogen, Grand Island, 
NY) and then sub-cultured with a 1:5 splitting ratio when the cells reached about 90% 
confluency. From the parental HeLa cells CSCs (termed simply as hCSCs in the rest of 
the document) were cultured following a modified protocol described by Gu et al. [246]. 
Briefly, single-cell suspensions of HeLa cells (4×104) were seeded into a 100-mm ultra-
low attachment (ULA) petri dish (Corning Inc., Corning, NY) containing 8 ml of serum-
free mammary epithelial basal medium (MEBM, Lonza, Allendale, NJ), supplemented 
with 1x B27 (Invitrogen, Grand Island, NY), 4 µg/ml heparin (Sigma-Aldrich, St. Louis, 
MO), 20 ng/ml hEGF, and 20 ng/ml hFGF (Invitrogen, Grand Island, NY). After an 
initial 5-day culture in suspension at 37 °C, an additional 9 ml of sphere culture medium 
was added for another 5 days of culture. On day 10, spheres were harvested by 
 113 
	
centrifugation at 500 x g for 3 minutes, followed by washing with phosphate-buffered 
saline (PBS), trypsinization with TrypLE for 10 minutes at 37 °C, centrifugation at 500 x 
g for 3 minutes, resuspension in 5 ml of hCSC culture medium, and counting with a 
hemocytometer. Both HeLa cells and hCSCs were used for flow cytometry experiments.  
 
Aldefluor assay 
The Aldelfluor Kit (STEMCELL Technologies, Vancouver, Canada) was used to 
determine the enzymatic activity of ALDH in HeLa and hCSCs. hCSCs were treated with 
PEITC (Sigma-Aldrich, St. Louis, MO) or dimethyl sulfoxide (DMSO, Sigma-Aldrich, 
St. Louis, MO) 24 hr prior to cell harvesting. Cells were trypsinized, washed with 1x 
PBS, and counted using a hemocytometer. Cells were then resuspended in Aldefluor 
buffer at a concentration of 2 × 105 cells/mL. Activated Aldefluor reagent (300 µM) was 
prepared following the manufacturer’s instructions. PEITC Cells were incubated with 
activated Aldefluor reagent and its control reagent, diethylaminobenzaldehyde (DEAB) at 
37°C for 45 min, with intermittent shaking after every 15 min.  Following incubation, all 
the tubes were centrifuged at 250 x g for 5 min at 4oC. Aldefuour-stained cells were 
washed once in Aldefluor buffer, and maintained in 4°C until acquired through FL1 
channel in flow cytometer (FACSCalibur, Becton, Dickinson and Company, San Jose, 
CA) as ALDH high and side scatter low phenotypes. 
 
ROS assay 
Cells were harvested, trypsinized, washed with 1x PBS, and counted using a 
hemocytometer before collecting in conical test tube. Using Cellular ROS Detection 
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Assay Kit (Abcam, San Fransisco, CA), the cells were stained with 20 µM 2’, 7’ –
dichlorofluorescin diacetate (DCFDA) in 1X Buffer supplied for 30 minutes at 37 °C 
following the manufacturer’s protocol. 2 x 105 hCSCs per sample were aliquoted into a 
six-well plate and incubated with 10 µM PEITC or DMSO control for 3, 6, or 9 hr at 37 
°C. GSH (Sigma-Aldrich, St. Louis, MO) was used as an inhibitor of the ROS production 
and a pro-oxidant hydrogen peroxide (H2O2) was used as a positive control in the assay. 
The read signal was detected at Ex485 nm/Em535 nm using a flow cyotometer.  
 
Flow cytometry 
Cells were washed with 2 ml of PBS, trypsinized with 1 ml of TrypLE, and 
resuspended in 1 ml of PBS, followed by immunostaining. Similarly, hCSCs were 
collected after 10 days of culture, trypsinized, and resuspended in 2 ml of PBS with a 
density of 1×106 cells/ml, followed by immunostaining. Cells were immunostained with 
anti-CD24–FITC (1:500 v/v, Millipore, Billerica, MA) or anti-CD44–FITC (1:500 v/v, 
Millipore, Billerica, MA) antibodies for 1 hour at room temperature. 
Immunofluorescence was measured using FACSCalibur cell analyzer (Becton Dickinson, 
San Jose, CA) with approximately 10,000 events in each sample. Propidium 
iodide/annexin V staining was performed according to the manufacturer’s instructions. 
Briefly, 5×105 cells were centrifuged and resuspended in 100 µl of 1x binding buffer 
(Invitrogen, Grand Island, NY). The cells were treated with 10 µM PEITC or vector 
control (DMSO) for a total of 24 h. The cells were then incubated with 5 µl of annexin 
V–FITC (eBioscience, Inc., San Diego, CA) and 5 µl of propidium iodide (eBioscience, 
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Inc., San Diego, CA) at room temperature for 5 minutes in the dark before acquiring at 
least 10,000 cells in a flow cytometer.  
 
Sphere-formation assay 
The hCSCs were enriched in spheres in serum-free medium. Sphere culture was 
carried out as previously described in the sphere culture section. Cells were treated with 
predetermined doses of 2.5, 5 or 10 µM of PEITC or DMSO as control. After 7 days 
incubation, photomicrographs of spheres were acquired under an inverted phase-contrast 
microscope (Olympus America Inc., Center Valley, PA), and the number of hCSCs was 
counted using a hemocytometer. 
 
Cell proliferation assay 
A standard colorimetric method (MTS assay) was used to determine the number 
of viable cells, which were harvested and counted with a hemocytometer before seeding 
into 96-well microplates at a density of 2×104 cells per well. Cells were cultured in 
DMEM supplemented with 100 U/ml penicillin, 100 µg/ml streptomycin, 5% heat-
inactivated FBS, and 50 µM 2-mercaptoethanol. hCSCs were treated with three 
concentrations of PEITC (2.5, 5, and10 µM). After 24 and 48 hours of incubation, 20 µl 
of CellTiter reagent was added directly to the cell-culture wells and incubated for 1 hour 
at 37 °C, followed by cell viability assessment using the CellTiter 96 AQueous One 
Solution Cell Proliferation Assay kit (Promega, Madison, WI), containing [3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, 
inner salt; MTS]. The manufacturer’s instructions were followed, and treatments were 
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compared with vehicle control (DMSO-treated cells) at 490 nm in a BioTek Synergy H4 
multimode plate reader (BioTek, Winooski, VT). 
 
Immunoblotting 
hCSCs (1×106) were seeded in each well of a 6-well plate and incubated 
overnight at 37°C in a 5% CO2 incubator. Old culture medium was replenished by culture 
medium containing 1.25, 2.5, 5 or10-µM concentrations of PEITC for 3 hours. Cell 
harvesting and immunoblotting were carried out as we previously reported [59]. Briefly, 
cells were lysed in ice-cold RIPA buffer containing 150 mM NaCl, 50 mM Tris (pH 8.0), 
10% glycerol, 1% Nonidet P-40 (NP-40), and 0.4 mM EDTA, followed by a brief 
vortexing and rotation for 30 minutes at 4 °C. Equal amounts (v/v) of cell lysates were 
separated by SDS-PAGE through a 12% separating gel, transferred to nitrocellulose 
membranes blocked with 5% non-fat dry milk, and double-probed overnight at 4 °C with 
mouse anti-human Sp1 (1:1000 v/v, Millipore, Billerica, MA) and rabbit anti-human β-
actin (1:5000 v/v, Millipore, Billerica, MA) antibodies. Blots were then washed in PBS 
and further incubated with secondary antibodies, goat anti-rabbit horseradish peroxidase 
(1:5000 v/v, Millipore, Billerica, MA), for 1 hour at room temperature. Finally, after 
rinsing in Tween20 (0.1% in PBS), blots were incubated for 5 min in enhanced 
chemiluminescent substrate for horseradish peroxidase (SuperSignal™ West Femto, 
Thermo Fisher Scientific, Waltham, MA) and imaged with a ChemiDoc XRS+ Imaging 
System (BioRad, Hercules, CA), followed by a mean fluorescence intensity analysis of 
Sp1 levels. 
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Tumorigenicity study in mice 
Animal studies were carried out in accordance with the guidelines of the 
Institutional Animal Care and Use Committee (IACUC), South Dakota State University 
(IACUC approval #12-087A). Sixteen female non-obese diabetic, severe combined 
immunodeficient (NOD/SCID, NOD.CB17-Prkdcscid/J) mice (Jackson Laboratories, Bar 
Harbor, ME), 5 weeks old, were randomly grouped into four groups (four mice per 
group) in specific pathogen-free (SPF) housing at a constant temperature of 24–26 °C 
with a 12-h:12-h light/dark cycle. All mice were allowed to acclimatize for 1 week and 
were provided with sterile food and water ad libitum. HeLa and hCSCs were cultured, 
trypsinized, washed, pre-treated with 10 µM PEITC where indicated, and resuspended in 
PBS at the concentration of 1×107 cells/ml before injecting into the mice. Each mouse 
was subcutaneously injected at both flank regions with one injection of PBS (100 µl, 
control group), HeLa (1×106), hCSCs (1×106), or hCSCs pretreated with 10 µM PEITC 
(1×106). The cell number in each injection was consistent with the study previously 
carried out by Gu et al. [246]. All mice were routinely monitored for tumor formation, 
weight loss, pain, and distress. The mice were euthanatized with CO2 asphyxiation 28 
days post-treatment. The average tumor number per injection was calculated in each 
group. 
 
Statistical analysis 
Statistical analyses were carried out using Sigma Plot software (Systat Software, 
Inc., San Jose, CA). Analysis of variance (ANOVA) followed by a Dunnett’s post hoc 
test was used to compare multiple means. Statistical significance between the groups was 
 118 
	
assessed by Student’s t test when compared two groups receiving similar treatments. Data 
were expressed as means ± SEM. Experiments were repeated at least three times. The 
significance of differences between means is represented by asterisks: *p≤0.05, 
**p≤0.01, ***p≤0.001. 
 
5.4. Results 
Sphere culture enriches ALDHhighCD44high hCSCs 
Since others and we have shown that sphere culture enriches the population of 
sphere-forming CSC-like cells in HeLa cervical cancer cell line [61, 246], we further 
seek to quantify this enrichment in HeLa cells through a well-established cervical CSC 
marker, ALDH1 [55]. In order to use Aldefluor assay we first optimized the proper 
concentration of hCSCs and found that 2 x 105 cells/ml produced the optimum signal 
intensity when compared to 5 x 105 and 1 x 106 cells/ml (data not shown). After growing 
the cells in serum free sphere-culture medium, 25.40 % of ALDHhi in HeLa cells at day 0 
significantly enriched (p<0.001) to 57.75 % at day 10 (Figure 5.1). On the contrary, HeLa 
cells grown for 10 days in complete growth medium with 10% fetal bovine serum (FBS) 
did not allow sphere formation and hence did not change ALDHhi cells (data not shown). 
These ALDHhi hCSCs were also confirmed to be CD44hi cells, further validating the 
sphere-culture mediated enrichment of hCSCs.  
 
PEITC inhibits the activity of ALDH1 in both HeLa cells and hCSCs 
PEITC inhibits ALDH2 in liver [244]. Since NCBI blast revealed that ALDH1 
and ALDH2 share 68% of amino acid sequences, we hypothesized that PEITC could also 
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inhibit ALDH1in CSCs. As expected, PEITC attenuated ALDHhi cells in HeLa cells 
when compared to DMSO control (15.82% vs 22.41%), using DEAB as a negative 
control for Aldefluor reagent Figure 5.2a). Similarly, PEITC (10 µM) also attenuated 
ALDH enrichment in hCSCs when compared to DMSO control (40.96% vs 56.71%), 
using disulfiram as a positive control (Figure 5.2c, 5.2d). We observed that both PEITC 
and disulfiram had similar ALDH1 inhibiting effects on hCSCs. Further, we sought to 
understand the dose response (1.25 – 10 µM) of PEITC on inhibiting ALDH1 in hCSCS. 
1.25 µM PEITC inhibited ALDHhi cells by 20% (p<0.01), where as 5 and 10 µM PEITC 
inhibited ALDHhi cells by around 40% and 65% (p<0.001), respectively (Figure 2e). 
Taken together, PEITC inhibited ALDH1, further attenuating the population of hCSCs. 
 
PEITC induces ROS in hCSCs 
Being an electrophilic in nature PEITC tends to covalently interact with 
nucleophilic GSH, leading to ROS-induction in cells [240]. Since CSCs possess high 
level of GSH as defensive machinery, we hypothesized that PEITC could selectively 
induce more ROS in hCSCs. DCFDA ROS assay revealed that PEITC (10 µM) increased 
ROS production by 1.4 fold higher than that of DMSO control using H2O2 (50 µM) as a 
positive control (Figure 5.3). Interestingly, when the PEITC-treated cells were 
replenished with GSH (25 nM), the cells came back to the normal redox status, further 
supporting the ROS induction by PEITC in hCSCs. 
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PEITC inhibits proliferation of hCSCs and induces apoptosis 
Sphere formation assay showed that the sphere-forming capacity of hCSCs was 
inhibited by PEITC in a dose dependent manner (Figure 5.4a). Moreover, the MTS 
cytotoxicity assay revealed PEITC significantly reduced the viability of hCSCs by around 
20% and 70% when treated for 24 hr and 48 hr, respectively with a concentration of 5 
µM (p<0.05) and 10 µM (p< 0.001) (Figure 5.4b). Propidium iodide and Annexin V 
assay revealed that PEITC (10 µM) significantly increased (p<0.01) the early apoptotic 
cells when compared with DMSO control (6.42% vs 3.89%) (Figure 5.4c). Together, 
PEITC showed its pro-apoptotic and anti-proliferative properties in hCSCs. 
 
PEITC inhibits Sp1 and P-gp proteins in hCSCs 
In our previous study [61], when compared to parental HeLa cells hCSCs caused 
more efflux of Hoechst 33342 dye, which is a substrate of multi-drug transporter P-gp 
protein [247]. Hence, we hypothesized that PEITC might inhibit P-gp protein in hCSCs. 
Flow cytometric analyses revealed that PEITC (10 µM) inhibited P-gp positive hCSCs 
when compared to DMSO control (4.5% vs 9%) (Figure 5.5c, 5.5d). Since 
Sp1transcription factor is involved in the binding of promoter region of MDR1 (P-gp) 
gene, we sought to understand if PEITC could inhibit Sp1 protein. Western blot followed 
by mean fluorescence intensity analyses showed that Sp1 protein was inhibited by PEITC 
in a dose dependent manner, using Sp1 inhibitor mithramycin as a positive control 
(Figure 5.5a, 5.5b). To confirm the correct band of Sp1 protein, we used HeLa nuclear 
extract as a positive control in a separate blot (data not shown).  
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PEITC inhibits CSCs in vivo and prevents metastasis in mice 
In order to confirm the higher tumorigenic potential of hCSCs in vivo and its 
attenuation by PEITC, we carried out a xenotransplant NOD-SCID mouse model with 
two treatment groups and a negative control group. Normal body weight and activity 
among all the groups confirmed that there was no alteration in food intake of the mice 
due to tumor development (data not shown). Equal number of hCSCs (1x106) with 10 µM 
PEITC pre-treatment (hCSC+PEITC) developed lower tumor load when compared to 
without PEITC pretreatment group (hCSC) (Table 5.1). Interestingly, mice in hCSC 
group started forming the tumors in only about 2 weeks.  Taken together, hCSCs initiated 
tumor formation and its tumorigenicity was attenuated by PEITC pre-treatment prior to 
xenotransplant. 
 
5.5. Discussion 
Absence of rigorous screening program has made the cervical cancer the second-
most-fatal cancer in women worldwide, especially more prevalent in developing nations 
[248]. Since others and we have shown that PEITC can induce the death receptor-
mediated extrinsic apoptosis pathway in human cervical cancer cell line and cervical 
cancer stem cells [61, 249], this study highlighted the intrinsic apoptotic pathway 
involving ROS and mitochondrial oxidative stress in cervical CSCs. Using aldefluor 
assay on hCSCs enriched through cervical HeLa sphere culture, here we showed for the 
first time that PEITC inhibited ALDH1, a marker of cervical cancer stem cells and 
induced ROS-mediated apoptosis in hCSCs through inhibition of Sp1 transcription factor. 
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20 years ago, Lindros et al. described PEITC as an inhibitor of mitochondrial 
ALDH in liver in the context of alcohol administration, with a similar effect as that of a 
known ALDH inhibitor, disulfiram [244]. This is due to accumulation of ethanol-
produced toxic acetaldehyde [250], which cannot be converted into acetic acid due to 
lack of ALDH2 enzyme. Interestingly, this old concept did not get much attention until 
ALDH was later proposed as a novel CSC marker in a breast cancer [52]. Since ALDH is 
functionally associated with redox balance in CSCs, an inhibition of ALDH1 by PEITC 
could induce ROS in CSCs (Figure 5.3). Despite the paradoxical role of PEITC, an 
antioxidant in lower doses and pro-oxidant in higher doses in normal healthy cells, its 
pro-oxidant role in cancer cells is well studied [243]. Intriguingly, another ALDH2 
inhibitor, disulfiram, has been associated with induction of ROS and inhibition of a CSC 
marker ALDH1 [251]. Moreover, sulforaphane, a closely related isothiocyanate to 
PEITC, has been already shown to inhibit ALDH1in breast CSCs [252], further 
supporting the CSC-targeted chemotherapeutics potential of PEITC.  
Previous study that showed PEITC modulate drug efflux transporter proteins like 
P-gp [253] in cisplatin-resistant gastric cancer cell line also supports our observation that 
PEITC ainhibits P-gp in CSCs (Figure 5.5). This could be one of the explanations for 
PEITC-associated sensitization of other conventional drugs, which are mostly effluxed 
through P-gp transporter [254], which is mediated through multidrug resistance gene 
(MDR1). Therefore, PEITC, either alone or in combination, may be useful as the 
therapeutic strategy for overcoming multi-drug resistance.  
Interestingly, promoter of the MDRl gene gets activated with specificity protein 
(Sp1) [235], which may link to its significantly higher expression in colon CSCs than 
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parent cancer cells [255]. Mechanistically, higher expression of Sp1 and related Sp 
proteins in cancer is governed, in part, by miroRNA-regulated transcriptional repressors 
like ZBTB proteins, which directly compete with Sp proteins to bind onto GC-rich 
promoter regions. In this context, recently it has been shown that PEITC induced 
glutathione (GSH)-dependent ROS in pancreatic cancer cells resulting a downregulation 
of miR-27a and miR-20a/miR-17-5p, which induced ZBTB10 and ZBTB4, respectively, 
and in turn inhibited Sp proteins [256]. Moreover, the Sp1 transcription factor is a target 
of histone acetylation associated with histone deacetylase (HDACs) inhibitors [236]. 
Since PEITC is also an HDAC inhibitor in prostrate cancer cells [257], Sp1 inhibition 
could be an important epigenetic mechanism of action for induced apoptosis due to 
PEITC and other ROS-inducing anticancer agents [256], further validating our findings in 
CSC-specific context that merit further study.  
In this study PEITC also induced ROS in 3 hr, and the effect was attenuated when 
the cells were replete with GSH (Figure 5.3). Since cellular redox homeostasis is 
dependent on GSH and thiol-regulating glutaredoxin enzyme system [258], PEITC 
utilizes this redox machinery to bind and deplete GSH, leading to ROS-induced cell 
apoptosis [243, 256]. Strikingly, CSCs that have higher levels of GSH are relatively more 
sensitive to PEITC, which may also explain its selectivity toward CSCs compared with 
cancer cells and normal cells. 1.5–10-µM final concentrations of PEITC used in this 
study are achievable following oral administration in human [259] and have been already 
used in our prior studies to induce apoptosis in the SW480 colon cancer cell line [59] and 
cervical cancer stem-like cells [61].  Hence, targeting CSCs with a natural compound 
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PEITC have significant implications on minimizing tumor recurrence and associated 
health care costs. 
 
5.6. Conclusion 
This novel study demonstrated that PEITC inhibited CSC marker ALDH1 and 
induced ROS-mediated apoptosis, inhibiting the proliferation and sphere-formation 
potential of hCSCs, which correlated with the less tumor counts in vivo. Since PEITC 
also suppressed Sp1 transcription factor and multi-drug resistance protein P-gp, this study 
provides a substantial proof-of-concept that PEITC targets cancer stem cells using HeLa 
CSCs as a model. Hence, PEITC commonly obtained from cruciferous vegetables can 
effectively target chemo-and-radiotherapy-resistant CSCs, fighting against the cancer 
relapse and associated healthcare-cost burden.  
 
5.7. Future Directions 
1. To sort the ALDHhi  cells using FACS and carryout the in vitro experiment,  
2. To inject CSCs in multiple concentrations to see the concomitant inhibitory 
effects PEITC concentrations in tumor inhibition in NOD/SCID mice 
3. To identify the active binding site of ALDH1 enzyme and to establish the role of 
cysteine in activity of PEITC 
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Figures and Legends 
 
 
Figure 5.1. Sphere culture enriches ALDHhiCD44hi hCSCs population from parental 
HeLa cells 
a) Representative FACS dot plots showing enrichment of ALDHhi cancer stem cells from 
day 0 to day 10 due to sphere culture in low anchorage dishes. The ALDHhi gated cells 
were mostly CD44 positive. b) Bar graphs representing ALDH enrichment in HeLa (Day 
0) and hCSCs (Day 10). All data represent means ± SEM, ***p ≤ 0.001 
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Figure 5.2. PEITC inhibits ALDH activity in HeLa and hCSC 
a) Representative FACS dot plots showing PEITC inhibits ALDH activity in HeLa cells 
(a) and hCSCs (c). b) Bar graphs showing the reduction of ALDH high cells in HeLa (b) 
hCSC, hCSC + PEITC, and hCSC + Disulfiram treatments, using Disulfiram as a positive 
control (d). e) Bar diagrams showing inhibition of ALDH high hCSCs by PEITC in a 
dose dependent manner. All data represent means ± SEM, *p ≤ 0.05, **p ≤ 0.01, 
***p ≤ 0.001. 
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Figure 5.3. PEITC induces ROS in hCSCs 
a) Representative FACS histograms showing PEITC induces ROS in hCSCs with H2O2 
as a positive control. b) Overlay image of histograms showing ROS induced by PEITC 
can be replenished by exogenous glutathione c) Bar diagram showing the ROS induction 
by PEITC in hCSCs.  
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Figure 5.4: PEITC inhibits proliferation of hCSCs and induces apoptosis  
a) Representative photomicrographs showing attenuation of hCSCs sphere formation 
(day 7) by PEITC in a concentration-dependent manner (400-µm scale). b) Bar graphs 
showing concentration-dependent effects of PEITC on the viability of hCSCs after 24 hr 
treatment (n=6). The dotted line represents the baseline cell viability for DMSO, which 
served as a control to determine statistical significance. c) Bar graphs showing the 
percentage of apoptotic cells obtained from propidium iodide and Annexin V assay. All 
data represent means ± SEM, *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001. Dr. Yi Liu and Dr. Dan 
Wang helped with this figure. 
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Figure 5.5. PEITC inhibits transcriptional factor Sp1 and multidrug resistance 
protein ABCB1 in hCSC  
a) Western blots showing PEITC inhibits Sp1 in a dose dependent manner and their 
corresponding bar graphs with relative Sp1 expression (b)   c) FACS histograms showing 
PEITC inhibits multi-drug resistance protein P-Gp (ABCB1) D) Bar graphs showing 
PEITC inhibits multi-drug resistance protein P-Gp (ABCB1). All data represent 
means ± SEM, *p ≤ 0.05. 
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Table 5.1. Number of tumors in treatment groups in NOD/SCID mouse model 
Cells Injected Tumors at week 2 
Tumors at 
week 4 
HeLa 0/8 3/8 
hCSC 1/8 4/8 
hCSC + PEITC  0/8 1/8 
NOD/SCID: Non-obese diabetic/severe combined immunodeficient  
hCSC: HeLa cancer stem cell 
PEITC: Phenethyl isothiocyanate
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CONCLUSIONS 
This dissertation study provides the evidence that dietary fiber RS4 
supplementation selectively changes the gut microbial and metabolite environment as 
well as associated host metabolic functions in a free living Caucasian cohort with signs of 
MetS. These results backed-up by in vivo study using a suitable mouse model of MetS 
further supports the perceived anti-inflammatory role of bacterial metabolites, 
particularly butyrate, in attenuating intestinal inflammation epigenetically. This study is 
also the first to further explain the role of maternal high fat diet on heart tissue-specific 
differential histone modifications in the rat offspring born to obese and/or diabetic 
pregnancy, highlighting the fuel-mediated cardiac dysfunction in offspring that increase 
the adult-onset of CVDs. Further, PEITC commonly obtained from cruciferous 
vegetables effectively target chemo-and-radiotherapy-resistant cancer stem cells, fighting 
against the cancer relapse and associated healthcare-cost burden. 
Further characterization of prebiotic functional fibers-associated epigenetic 
alterations may provide effective strategies to mitigate the low-grade inflammation in the 
context of intestinal as well as extra-intestinal diseases associated with dysbiosis. In 
addition, identification of the reversible epigenetic landscape in utero and its association 
to risks for adult-onset of chronic CVDs provides an effective strategy for novel cardio-
metabolic health management in next generation and future generations. Hence, this 
study enhances the knowledgebase of nutritional therapies with important implications 
for dietary guidelines to decrease the high fat with an increase in fiber and vegetables 
consumption in our daily meal for all individuals in all life stages.  
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